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Advances in understanding the complexity of cellular mechanisms depend upon 
methods that can quantify affinity interactions between biological molecules.  
Additionally, fields such as chemical biology and drug discovery require methods for 
identifying molecules that can probe these affinity interactions.  Aptazymes are RNA-
based enzymes that catalyze chemical reactions in response to binding interactions with 
targets of interest, making them suitable for use in quantifying affinity interactions and 
screening for bioactive molecules.  Much of the promise of aptazymes comes from the 
ability to design or select them for chosen target molecules, and remains unexplored as 
relatively few of the known aptamers have been appended to ribozymes to create 
aptazymes.  The analytical potential, which arises from the unique and tunable ability of 
these molecules to translate effector binding into a detectable signal in the form of an 
RNA cleavage reaction, is also still in early stages of development. 
We have developed glucosamine-6-phosphate (GlcN6P) sensitive assays that 
detect substrate cleavage by the naturally occurring GlcN6P-dependent glmS ribozyme 
via either fluorescence resonance energy transfer (FRET) or capillary electrophoresis 
with laser induced fluorescence (CE-LIF).  We achieve a dynamic range extending from 
0.5 to 500 μM GlcN6P when turning over a single substrate.  Signal amplification and 
13-fold increased sensitivity are achieved under multiple-turnover reaction conditions.   
We have analyzed aptazymes that are activated by ATP and cAMP for 
compatibility in multiplexed assays and developed a qualitative assay for these molecules 
 xiv 
based on polyacrylamide gel electrophoresis (PAGE) with fluorescence detection.  We 
also developed a multiplexed assay for simultaneous detection of GlcN6P and ATP using 
the glmS ribozyme and ATP aptazyme.  This assay detects GlcN6P with a limit of 
detection (LOD) of 40 nM and ATP with an LOD of 1 M.  Our assays demonstrate the 
potential of aptazymes, in conjunction with FRET, CE-LIF, and PAGE detection, to serve 







Affinity interactions are abundant in nature and are useful for analytical 
applications.  They have found use in elucidating interesting biological phenomena, 
detecting and quantifying relevant molecules, and show promise in areas such as 
pharmaceutical development.  Toward these ends, various probing molecules have been 
used, including antibodies, peptides, small molecules, and nucleic acids in methods such 
as gel mobility shift assays, western blotting, and immunoassays.   
The development of nucleic acid-based methods for the detection of biomolecules 
involves recognition and transduction elements and a method of detection.  Aptamers 
and aptazymes have served in these roles with a variety of different detection systems.  
Of the two, aptamers have been more extensively studied, with the use of aptazymes as 
analytical agents a promising and relatively open area for research. 
 
Aptamers and aptazymes 
Aptamers.  Aptamers are nucleic acids molecules that have been evolved to 
have non-natural binding interactions with targets of interest, making them suitable for 
application in quantifying affinity interactions and screening for bioactive molecules.
1
  
The sensitive and specific binding characteristics of aptamers make them useful 
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candidates for diagnostic, therapeutic, and analytical applications.  Aptamers are 
obtained through Selective Evolution of Ligands by EXponential enrichment (SELEX), a 
combinatorial ligand discovery process that starts from large, synthetic libraries of 
random-sequence nucleic acid molecules to isolate ligands with high affinity and 
specificity for molecular targets.
2-4
  In SELEX, an oligonucleotide library is exposed to 
the target of interest, and subsets of sequences that have affinity are partitioned from 
those sequences with little or no affinity.  The process is iterative, typically involving 
ten to fifteen rounds of selection with increasing stringency and ending when a set of 
ligands with the desired binding characteristics is obtained.  SELEX has been used to 
isolate molecules to a broad range of targets, from small molecules to large proteins.
5
  
  RNA base pairing and other sequence dependent intramolecular interactions 
vary among the library molecules, providing a large number of different tertiary 
structures in the population.  Among these are commonly recognized motifs: hairpins, 
bulges within helices, pseudoknots, and G-quartets.  Biological function, including 
binding affinity, is determined by the intramolecular interactions of each molecule.
6
 
Affinities of aptamers for their target molecules can be quite high, with 
dissociation constants extending into the picomolar range.
7, 8
  These affinities rival or 
exceed the capabilities of antibodies, making aptamers good candidates for analytical 
assays.  The evolution process enables control over kinetic and thermodynamic 
properties of the aptamer-target binding interaction.
9
 
Aptamers have been demonstrated as viable replacements for antibodies in many 
immunological experiments.  In fact, oligonucleotides provide significant advantages 
over antibodies in several regards.
9
  Many of these are a result of the evolution process, 
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which allows the in vitro development of aptamers as opposed to the in vivo development 
of antibodies.  The in vitro selection process confers the advantage of a wider range of 
target molecules by including those that would be toxic in vivo as well as those that 
would not induce an immune response.  Due to the reliability of chemical synthesis of 
aptamers after they have been sequenced, less batch-to-batch variation is expected than is 
expected for antibodies, which are always produced from animals or cell culture.  
Aptamers are more stable for long-term storage than antibodies, and can be restored even 
after denaturation.  Aptamers can be modified after selection to further optimize binding 
affinities or to add modified bases to prevent degradation if they will be introduced to 
biological samples.  Further, no immunogenicity is expected from aptamers if they are 
introduced to the body.  Finally, reporter molecules such as fluorescein and linkers such 




Aptamers also have some disadvantages when compared to antibodies, and 
researchers are currently working to improve these areas.  Aptamers, especially RNA 
aptamers, may suffer from degradation in biological samples.
11
  Non-natural bases have 
helped to reduce this problem.
1
  The significant negative charge of nucleic acid 
molecules may make selection for binding to negatively charged targets difficult, though 
selection for binding to some such molecules has been successful.
9
  While commercial 
production of antibodies is routine, there is no such process for obtaining aptamers.  One 
company, SomaLogic (Boulder, CO), is developing aptamers for a variety of proteins to 
be used in array format for clinical biomarker detection.
12
  They have informally offered 
to develop aptamers for any protein with which they are provided.   While this 
 4 
technology is still in development, research into the applicability of these molecules in 
analytical techniques is also being developed. 
Aptamers have been developed for many targets and have been used in a number 







 and specific detection and precise quantification of 
molecules.
1, 9, 16, 17
  Aptamer affinity interactions have been monitored with a myriad of 
analytical instrumentation including flow cytometry,
18





 fluorescence resonance energy 
transfer (FRET),
17
 and affinity chromatography.
9, 13, 21, 22
  
Aptazymes.  RNA is a widely studied biopolymer that is involved in cellular 
functions ranging from protein biosynthesis to catalysis of chemical reactions and 
regulation of gene expression by RNA interference and riboswitches.
23-25
  Catalytic 
RNA‟s, or ribozymes, catalyze the cleavage or ligation of the RNA phosphodiester 
backbone.
26
  While combinatorial chemistry methods have resulted in the in vitro 
development of aptamers,
10
 further development by coupling aptamers with ribozymes 
has resulted in allosterically regulated ribozymes, or aptazymes, which catalyze cleavage 
reactions as the result of the binding of specific effector ligands.
27
  To date, one 
naturally occurring aptazyme has also been identified, which is the glmS ribozyme.
28
  
Some aptamers exhibit conformational changes as they bind their targets with 
high affinity, making them a natural choice for allosteric function.  Aptazymes typically 
regulate catalytic function via conformational changes that are induced by the binding of 
effector molecules at sites distinct from their active sites.  Interestingly, this is not true 
for the naturally occurring glmS ribozyme, as its effector acts as a cofactor rather than 
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inducing a conformational change.
29
 An engineered aptazyme can be thought of as 
consisting of three domains: an effector binding center, a catalytic center, and a 
communication domain bridging the two.  Aptazymes can be generated by SELEX by 
adding an additional selection step for catalytic function or they can be designed 
rationally, taking advantage of the modular nature of RNA by joining three domains, one 
with each of the above functions.  That is, coupling a known aptamer to a known 
ribozyme via a communication domain.  Typically some variation is introduced into the 
communication domain to select for sensitive and specific response to the effector.  
Much of the promise of these molecules comes from the power of this coupling, and 
remains unexplored as relatively few of the known aptamers have been appended to 
ribozymes to create aptazymes.  The analytical potential, which arises from the unique 
and tunable ability of these molecules to translate effector binding into a detectable signal 
in the form of a cleavage reaction, is also still in early stages of development. 
The hammerhead ribozyme has been used most extensively for aptazyme design.  
It is a naturally occurring self-cleaving ribozyme that is found as a part of some plant and 
animal pathogens.  Its structure is relatively simple and well characterized.  The 
hammerhead motif is a three stem junction with much of the core sequence conserved.  
It catalyzes cleavage of the nucleic acid backbone via transesterification chemistry that 
generates 5‟-hydroxyl and 2‟,3‟-cyclic phosphate termini.
30
   
Different kinds of libraries can be used for allosteric selection.  The random 
region is typically one or two domains of an otherwise rationally designed aptazyme (the 
communication or effector binding domains).  Whichever design is used for the library, 
an ideal selection scheme involves both positive and negative selection steps in each 
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round of selection.  The negative selection step involves incubation under selection 
conditions in the absence of effector.  Species that catalyze aptazyme cleavage are 
removed.  The positive selection step follows where molecules that catalyze cleavage in 
the presence of effector are retained, amplified, and put through another round of 
selection.  In this way, the library is enriched for catalytic aptazymes over several 
rounds.  Additional negative selection steps can be applied in order to remove 
aptazymes that are activated by molecules similar to the desired effector.
1
 
In an aptazyme assay, the effector ligand can be detected by monitoring the 



























  Some of these have been shown to function as recognition and 
transduction elements for assays in complex chemical and biological samples.
17, 27, 42, 50
 
glmS ribozyme.  The glmS ribozyme is a natural aptazyme that undergoes a self-
cleavage reaction in the presence of glucosamine-6-phosphate (GlcN6P).
28
  This 
ribozyme is located in an untranslated region upstream of the glmS mRNA in B. subtilis, 
where it serves to downregulate the glmS gene in response to the metabolic product of the 
GlmS enzyme, glutamine-fructose-6-phosphate amidotransferase, an intermediate in cell 
wall biosynthesis, by degrading the mRNA.  The GlcN6P metabolite modulates the 
catalytic rate of this ribozyme and thus the availability of the glmS gene product.  In 
many aptazymes, the ligand dependent cleavage rate is attributed to a conformational 
change that occurs upon ligand binding, but we and others have recently shown that this 
adaptive binding is not observed with the binding of GlcN6P. 
29, 51, 52
  Instead, GlcN6P 
 7 
is thought to play a catalytic role in the cleavage reaction,
29
 and the reaction has been 
demonstrated to be relatively specific for GlcN6P, showing no cleavage with many 
molecules structurally similar to GlcN6P and a substantially reduced rate of cleavage 
with a few molecules, like glucosamine.
28, 29, 51, 53
  This specificity makes the glmS 
ribozyme promising for use in analytical assays. 
As an analyte, GlcN6P is potentially interesting in at least two different systems.  
In bacteria, GlcN6P is a precursor in cell wall biosynthesis.  Therefore, identification of 
compounds that could activate glmS ribozyme cleavage and potentially inhibit cell wall 
biosynthesis could be advantageous in drug discovery.  The glmS ribozyme is highly 
conserved in genomes of some bacterial pathogens, like Bacillus anthracis and 
Staphylococcus aureus, making it a relevant detection target.
54
  GlcN6P is involved in 
the hexosamine biosynthetic pathway, which is ubiquitous in all organisms, and whose 
major end products are essential sugar building blocks for biosynthesis of peptidoglycan 
in bacteria, chitin in fungi and glycoproteins in mammals.
55
  The first and rate limiting 
step in this synthesis is the conversion of fructose-6-phosphate into GlcN6P.  One to 
three percent of cellular glucose that is converted to fructose-6-phosphate (Fru-6P) enters 
this pathway, and increased flux into this pathway has been shown to result in impaired 
ability of insulin to stimulate glucose uptake.
56
  Detailed characterization of this 
pathway could lead to insight into a mechanism of development of insulin resistance in 
cells.   
Several methods have been developed for monitoring GlcN6P formation in this 
pathway.  They include a colorimetric Morgan-Elson assay;
57
 a radiometric assay with 
14
C-fructose-6P as substrate and detection to 1 pmol;
58
 an HPLC assay of o-
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phthaldialdehyde derivatized GlcN6P, which can detect as little as 5 pmol;
59
 and a 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOFMS) assay, which can detect into the low nmol range.
60
  These all require multiple 
derivatization steps and/or radioactivity.   
cAMP, cGMP, and ATP aptazymes.  By rational design, coupling an RNA 
aptamer to the hammerhead ribozyme via a variable communication domain, the Breaker 
group built an aptazyme for ATP.
32
  The ATP aptamer was selected separately, and has 
a Kd of 0.7 M. The aptamer also binds to adenosine and AMP with similar affinities.
61
    
While a rational design strategy for obtaining aptazymes is appealing, not all aptamers 
effectively induce conformational change and, thus, aptazyme cleavage upon binding. 
32
    
Using in vitro selection, the Breaker group developed aptazymes that respond to 
cAMP and cGMP.
37
  This “allosteric selection” scheme applied selective pressure to a 
hammerhead ribozyme that was coupled to a 25 nucleotide random sequence domain via 
a known communication domain.  In negative selection steps, the library was incubated 
in the absence of effector under reaction conditions and uncleaved precursors were 
isolated by PAGE and subjected to positive selection in the presence of the effector 
molecules.  The cleaved 5‟ products were purified by PAGE and amplified.  In later 
rounds of negative selection, the library was incubated with alternate cNMP‟s to remove 
any that had cross-reactivity.  The cGMP aptazyme was further optimized for higher 
affinity binding by mutagenization and reselection.
38
  The apparent dissociation 
constants for these aptazymes were determined by measuring the half maximal cleavage 
activity.  For the cGMP aptazyme, the apparent Kd is 200 M.  The apparent Kd for the 
cAMP aptazyme is 500 M.
38
  These aptazymes are activated by a conformational 
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change caused by effector binding.  The weak affinities are expected to prevent assays 
using these aptazymes from rivaling LOD‟s obtained in current assays. 
Assays for ATP can be used to determine cell viability because it is the major 
source of metabolic energy.  Detection of ATP is also used to study some of the many 
cellular processes in which it is involved, which include biosynthetic reactions and signal 
transduction pathways, where ATP is used as a substrate by kinases that phosphorylate 
proteins and lipids, as well as by adenylate cyclase, which uses ATP to produce the 
second messenger molecule cAMP.  Detection of cAMP can be used to study signal 
transduction and enzyme activity.  
Commercial kits are available for the detection of ATP, cAMP, and cGMP with 
detection limits that are in the pM range.  Immunoassays for these molecules have 
traditionally involved radiochemical formats, but many are now fluorescence or 
bioluminescence based.  With the current stage of development of aptazymes, it is not 
realistic to expect that they will offer similar LOD‟s.  Perhaps the most interesting 
characteristic of an aptazyme system is the ability to design or develop aptazymes for a 
wide range of interesting analytes, which could include ones that are currently difficult to 
detect.  For now, proof-of-principle assays are called for that demonstrate the potential 
of this interesting group of molecules in analyte detection. 
 
Detection of Transduced Signal 
Analyte detection based on aptazymes has potential advantages over detection 
based on antibodies and protein enzymes, which have been the workhorses in molecular 
recognition for analytical assays.  Many of the potential advantages of oligonucleotide 
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reagents, such as ease and reproducibility of manufacture, come from the ability to 
chemically synthesize nucleic acids.
62
  Aptazymes also offer the advantage over 
aptamers of detection of even transient binding events.  After aptazyme cleavage, the 
products of the catalyzed reaction remain, even if the target molecule rapidly dissociates. 
Employing ribozymes in analytical assays requires the development of a reliable 
method for quantitatively detecting the cleavage reaction.  Ideally a detection method 
uses a minimal amount of sample, is fast, can be run in parallel or in array formats, and 
does not require elaborate design of the reagents.  Previous ribozyme assays have 
followed conversion of substrate into cleavage product by a variety of separation based 
and real-time methods.  Polyacrylamide gel electrophoresis (PAGE) has been the most 
widely used technique for monitoring ribozyme cleavage.  Use of PAGE involves 
removing aliquots from a cleavage reaction at various time points, stopping the reactions, 
and separating them in parallel on a gel, often with detection and quantification achieved 
by radiolabeling the RNA.  The collection of these data is tedious, results in relatively 
poor temporal resolution, and typically involves hazardous radioisotopes.  In some 
cases, HPLC separation has been employed, alleviating the need for radioisotopes, but it 
is neither a real-time nor high-throughput tool.
63-65
  Capillary gel electrophoresis (CGE) 
has also been used to separate and detect ribozyme cleavage and has been applied in high 
throughput in a microchip-based assay.
66, 67
  Some real-time methods have been used, 





fluorescence resonance energy transfer (FRET). 
71-73
  These methods provide precise 
determination of rate constants, but can suffer from sources of fluorescence change 
outside of bond cleavage and the possibility that cleavage is spectroscopically silent.   
 11 
Fluorescence resonance energy transfer (FRET).  Fluorescence resonance 
energy transfer, or Förster transfer, originates from the non-radiative transfer of energy 
between two fluorophores, a donor and an acceptor, by the coupling of transition dipoles 
through space.  Excitation of the donor fluorophore results in transfer of energy to the 
acceptor rather than radiative emission.  The acceptor then emits at its characteristic 
wavelength, and a unique excitation/emission spectrum is observed.
74
  The rate of 
energy transfer, kT, is strongly dependent on the distance, R, between the fluorophores.  
Thus, the energy transfer efficiency, ET, is also dependent on distance, demonstrated by 































  (1-2) 
 
where D is the donor fluorescence lifetime in the absence of the acceptor and R0 is the 
Förster distance at which ET is 50%.  R0 is characteristic of the fluorophore pair used, 
dependent on their spectral overlap and the relative spatial orientation, and ranges from 
20 to 90 Å.  This range allows the measurement of fluorophore distances ranging from 
10 to 100 Å, a relevant range for detecting ribozyme cleavage.
71
  This real-time 
technique can be used to precisely determine the rate of a ribozyme cleavage reaction 
with a temporal resolution of seconds or better.  
FRET has been widely used in the study of cleavage kinetics and global changes 
in RNA conformation.
71-73, 75
  By attaching a pair of fluorophores to different locations 
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on a nucleic acid molecule, relative distances between the labeled sites can be identified 
and monitored in real-time by steady-state FRET while conformational or catalytic 
changes occur.  In a ribozyme designed for FRET, donor and acceptor fluorophores are 
positioned on the RNA so that they are relatively close before ribozyme cleavage, thus 
energy transfer is observed.  After cleavage and dissociation of the cleavage product, the 
distance between the fluorophores increases.  The resulting decrease in FRET ratio 
(Iacceptor/Idonor) and increase in donor fluorophore emission (Idonor) are monitored in real-
time (Figure 1-1) to precisely determine the rate of a ribozyme cleavage reaction with a 
1-s temporal resolution or better.  Such temporal resolution allows observation of 
structural dynamics and precise determination of rate constants.  Disadvantages of 
FRET include the requirement for two fluorophores, the addition of which is expensive 




   
Figure 1-1: FRET response to ribozyme cleavage.  Before analyte addition, energy from incident light is 
transferred from donor to acceptor fluorophore.  After addition, analyte binds and the substrate is cleaved, 
releasing the cleavage product, resulting in an increase in donor fluorescence and decrease in acceptor 
fluorescence and FRET ratio. 
Capillary electrophoresis (CE).  Free-solution CE relies on differences in 
charge-to-size ratio of components to separate mixtures.  It rapidly separates analytes on 
the basis of their electrophoretic mobility, e, in free solution in a narrow bore fused 
silica capillary with high efficiency due to the application of high electric fields (Figure 
1-2).  Analyte mobility is proportional to charge, q, and inversely proportional to 







       (1-3) 
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The sum of the analyte mobility and the bulk, electroosmotic flow, eof, in the capillary 
determine the apparent mobility, app, of the analyte and the product of app and the 
applied electric field, E, determine analyte velocity, , in the capillary: 
EEv eofeapp )(         (1-4) 
Thus, even negatively charged nucleic acids can be separated with normal polarity, 
toward the negative electrode, when the electroosmotic flow is greater than the analyte 
mobility.  In our assays, detection is achieved by laser-induced fluorescence (LIF), 
which offers increased sensitivity over UV detection. 
 
 
Figure 1-2: CE response to ribozyme cleavage.  After cleavage reaction, uncleaved substrate is separated from 
fluorescent cleavage product.  
Free-solution CE has been used on many biochemical systems, including those for 
which gel electrophoresis has been traditionally used for analysis, and has had application 
in separation of DNA and protein mixtures.
20, 76, 77
  These have included studies of 
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aptamer-protein interactions by affinity probe CE, in which the aptamer was fluorescently 
labeled and mixed with protein.  The aptamer-protein complex could then be separated 
from free aptamer, when the separation time is short enough to prevent dissociation.
16, 19, 
78-80
  CE has also been used to monitor enzyme reactions, in which substrate is 
converted into a product, as with an aptazyme cleavage reaction.  Repeat injection of a 
sample over time allows for determination of kinetic properties of the system, as the 
increase in product formation (or substrate depletion) is monitored over time.
81, 82
 
CGE separates molecules based on electrophoretic mobility in a capillary through 
a sieving matrix, in a capillary in which electroosmotic flow has been eliminated, 
typically by coating the inner walls.  Capillary gel electrophoresis (CGE) is widely used 
for the separation of nucleic acid molecules, especially of DNA.  It has been used to 
observe ribozyme cleavage, with separation achieved in hydroxyethyl cellulose in a 
capillary
66
 and in linear polyacrylamide in a microchip, with overlapping, automated 
capillary injections.
67
   
Free solution CE and CGE have many advantages over slab gel electrophoresis 
including higher resolution, higher sensitivity, shorter analysis time, better quantification, 
less reagent consumption, and ease of automation.  
  
Dissertation Overview 
 The overall objective of this work was to develop FRET and CE-LIF based assays 
for the detection and quantification of small molecules using aptazymes.  First, an assay 
for GlcN6P was developed using the glmS ribozyme for recognition and transduction in 
single turnover reactions.  Detection was achieved by FRET and CE-LIF.  Both 
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methods were also used to monitor the cleavage reaction and obtain kinetic information.  
This assay was improved through the use of multiple turnover reaction conditions.  
Signal amplification was achieved at long times by holding the reaction at 50 °C, where 
the data suggest that the rate-limiting step is the binding of substrate to the ribozyme.  
The assay was further improved by cycling the temperature between a reaction 
temperature, 42 °C, at which the cleavage reaction is fast and seems to be limited by the 
off rate of the substrate from the ribozyme, and a dissociation temperature, 60 °C, at 
which substrate dissociation occurs.  The potential for developing a multiplexed system 
in which two substrates can be simultaneously detected by two ribozymes was explored 
after characterizing two additional aptazymes, for ATP and cAMP.  In a proof-of-
principle, the ATP aptazyme was multiplexed with the glmS ribozyme to detect ATP and 
GlcN6P, with separation by gel electrophoresis.  The ATP aptazyme is cross-activated 
by cAMP, so while a qualitative assay is possible, a quantitative, multiplexed assay of 
these two compounds is not achievable.  These assays demonstrate the potential for 
aptazymes to serve as recognition and transduction elements in analytical assays.  They 
also elucidate a need for further improvement in sensitivity and specificity of aptazymes 
for use in analytical assays.  
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CHAPTER 2 
ASSAY FOR GLUCOSAMINE-6-PHOSPHATE USING A LIGAND-ACTIVATED 
RIBOZYME AND FRET OR CE-LIF DETECTION 
 
Introduction 
RNA is a widely studied biopolymer that is involved in a myriad of cellular 
functions ranging from protein biosynthesis to catalysis of chemical reactions and 
regulation of gene expression by RNA interference and riboswitches.
23-25
  Catalytic 
RNAs, or ribozymes, catalyze the cleavage or ligation of the RNA phosphodiester 
backbone.  Riboswitches are non-coding, 5‟ leader regions of mRNA that bind small 
molecules with high specificity and subsequent modulation of transcription, translation, 
or mRNA processing.
83
  Combinatorial chemistry methods have resulted in the in vitro 
development of nucleic acid molecules that bind small molecules and proteins.
10
  
Further development has resulted in allosterically regulated ribozymes, or aptazymes, 
which catalyze cleavage reactions as the result of the binding of specific effector 
ligands.
27



























  To date, only one naturally occurring aptazyme has been 
identified, which is the glmS ribozyme, a catalytic riboswitch.
28
 
 The glmS ribozyme undergoes a self-cleavage reaction in the presence of 
glucosamine-6-phosphate (GlcN6P).
28
  In many aptazymes, the ligand dependent 
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cleavage rate is attributed to a conformational change that occurs upon ligand binding, 
but it has been shown that this adaptive binding is not observed in the case of the glmS 
ribozyme.  Instead, GlcN6P is thought to play a catalytic role in the cleavage reaction.  
The reaction has been demonstrated to be relatively specific for GlcN6P, showing no 
cleavage with many structurally similar molecules to GlcN6P and a substantially reduced 
rate of cleavage with a few molecules, like glucosamine.
28, 29, 51, 53
    This specificity 
makes the glmS ribozyme promising as an model system for an analytical assay.   
The specificity of the binding interactions and resultant signal transducing 
cleavage reactions of aptazymes make them appealing for use as analytical reagents.  In 
an aptazyme assay, the effector ligand can be detected by monitoring the cleavage 
reaction.  Indeed several assays that utilize aptazymes as a recognition element have 
been reported.
17, 27, 42, 50
 
Analyte detection based on aptazymes has potential advantages over detection 
based on antibodies and protein enzymes, which have been the workhorses in molecular 
recognition for analytical assays.  Many of the potential advantages of oligonucleotide 
reagents, such as ease and reproducibility of manufacture, come from the ability to 
chemically synthesize nucleic acids.  In some cases, their affinities rival or exceed the 
capabilities of antibodies, while the evolution process enables control over kinetic and 
thermodynamic properties of the aptamer-target binding interaction.   The in vitro 
selection process also confers the advantage of offering response to a wider range of 
target molecules by including those that would be toxic in vivo as well as those that 
would not induce an immune response.  Due to the reliability of chemical synthesis of 
aptamers after they have been sequenced, less batch to batch variation is expected than is 
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expected for antibodies, which are produced in vivo.  Aptamers are more stable for long-
term storage than antibodies, and can be restored even after denaturation.  Aptamers can 
be modified after selection to further optimize binding affinities or to add modified bases 
to prevent degradation if they will be introduced to biological sample.  Further, no 
immunogenicity is expected from aptamers if they are introduced to the body.  Finally, 
reporter molecules such as fluorescein and linkers such as biotin can often be easily 
attached to aptamers at precise locations without disrupting their activities.
62
 
Employing ribozymes in analytical assays requires the development of a reliable 
method for quantitatively detecting the cleavage reaction.  Ideally a detection method 
should use a minimal amount of sample, is fast, can be run in parallel or array formats, 
and does not require elaborate design of the reagents.  Previous ribozyme assays have 
followed conversion of substrate into cleavage product by a variety of separation based 
and real-time methods.  PAGE has been the most widely used technique for monitoring 
ribozyme cleavage.  Use of PAGE involves removing aliquots from a cleavage reaction 
at various time points, stopping the reactions, and separating them in parallel on a gel, 
often with detection and quantification achieved by radiolabeling the RNA.  The 
collection of these data is tedious, results in long analysis times, and typically involves 
hazardous radioisotopes.  In some cases, HPLC has been employed, alleviating the need 
for radioisotopes, but it is neither real-time nor high throughput.
63-65
  Capillary gel 
electrophoresis (CGE) has also been used to separate and detect ribozyme cleavage and 
has been applied in high throughput in a microchip-based assay.
66, 67
  Some real-time 









These methods provide precise determination of rate constants, but can suffer from 
sources of fluorescence change outside of bond cleavage and the possibility that cleavage 
is spectroscopically silent.  This paper describes the use of FRET and the first 
application of free-solution capillary electrophoresis (free-solution CE), that is gel-free 
nucleic acid separation, for monitoring ribozyme cleavage.   
FRET is an effective method for observing ribozyme cleavage.
71-73
  In a FRET-
designed ribozyme, donor and acceptor fluorophores are positioned on the RNA so that 
they are relatively close before ribozyme cleavage, but separate after cleavage and 
dissociation of the cleavage product.  The resulting decrease in FRET and increase 
donor fluorophore emission are monitored in real-time to precisely determine the rate of a 
ribozyme cleavage reaction with 1 second temporal resolution or better.  This temporal 
resolution allows observation of structural dynamics and precise determination of rate 
constants.  Some disadvantages of FRET include the requirement for two fluorophores, 
the addition of which is expensive and time consuming, and its sensitivity to quenching.   
Capillary gel electrophoresis (CGE) is widely used for the separation of nucleic 
acid molecules, especially of DNA.  It has been used to observe ribozyme cleavage, 
with separation achieved in hydroxyethyl cellulose in a capillary
66
 and in linear 
polyacrylamide in a microchip, with overlapping, automated capillary injections.
67
  
Free-solution CE has been extensively used on biochemical systems, including those for 
which gel electrophoresis has been commonly used for separation, and has had 
application in separation of DNA and protein mixtures.
20, 76, 77
  These have included 
studies of aptamer-protein interactions.
16, 19, 78-80
  In this work, we demonstrate the utility 
of free-solution CE in the detecting ribozyme cleavage.    Free-solution CE and CGE 
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have many advantages over slab gel electrophoresis including higher resolution, higher 
sensitivity, shorter analysis time, and better quantification.  
As a model system, we explore use of the glmS ribozyme to detect GlcN6P.  The 
specificity of the glmS ribozyme for GlcN6P and its modulated rate in response to 
GlcN6P make the ribozyme interesting for use in an assay for GlcN6P.  The cis-
cleaving glmS ribozyme has previously been investigated in a GlcN6P assay using 
fluorescence polarization.
40
 A minimal, trans-cleaving glmS construct has previously 
been developed and demonstrated to be similar in activity to the naturally occurring cis-
ribozyme.
51
  A similar trans-cleaving ribozyme has been used in a FRET based assay.
54, 
84
  In the trans model developed previously in the Walter lab, an external substrate is 
added to the glmS ribozyme and GlcN6P activated cleavage results in three RNA 
molecules: the cleavage product, a three nucleotide molecule; the cleaved substrate at 
eight nucleotides; and the unchanged ribozyme molecule, which is twenty three 
nucleotides in length.
51
  The kinetics of this reaction were monitored by FRET and free-
solution CE and each technique was used in development of an analytical assay.  This 
work demonstrates the potential utility of coupling FRET or CE with ribozymes for the 
detection and quantification of small molecules.  
     
Experimental Section 
Chemicals.  Unless stated otherwise, all chemicals used in the experiments were 
purchased from Sigma-Aldrich Co. (St. Louis, MO).  Tris-glycine buffer (10×) was 
purchased from Bio-Rad laboratories (Hercules, CA).  All solutions were prepared with 
deionized water from an E-Pure water purification system (Barnstead International Co., 
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Dubuque, IA).  Rhodamine 110 was purchased from Molecular Probes (Eugene, OR).  
RNA was purchased from the Howard Hughes Medical Institute Biopolymer/Keck 
Foundation Biotechnology Resource RNA Laboratory at the Yale University School of 
Medicine (New Haven, CT). 
Preparation of RNA.  The substrate strand contained 29-protection groups and 
was deprotected as recommended by the manufacturer and purified as previously 
described.
85, 86
 For FRET measurements, the substrate strand was modified on the 59 and 
39 ends with fluorescein (donor) and tetramethylrhodamine (acceptor), respectively, as 
also previously described.
73
  RNA concentrations were calculated from their absorption 
at 260 nm and corrected for the additional absorption of fluorescein and 
tetramethylrhodamine by using the relations A260/A492 = 0.3 and A260/A554 = 0.49, 
respectively. The ribozyme strand was generated by run-off transcription from a double-
stranded, PCR amplified template that encoded an upstream T7 promoter. Transcriptions 
were purified as previously described (Harris et al. 2004), and the RNA concentration 
was calculated as described above.   
FRET and CE cleavage kinetics reactions.  Single-turnover cleavage reactions 
to compare FRET and CE kinetics were performed under the following conditions: 50 
mM HEPES-KOH, pH 7.5; 200 mM KCl; 25 mM DTT; and 20 mM MgCl2.  Ribozyme 
and substrate concentrations were 20 nM and 10 nM, respectively for FRET experiments 
and 1000 nM and 500 nM, respectively, for CE experiments.  The ribozyme and 
substrate strands were annealed at 70 °C for 2 min, then cooled to room temperature over 
5 min before reacting at 25 °C.  Cleavage was monitored as described below. 
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FRET cleavage assay.  Single-turnover cleavage reactions were performed 
under the following conditions: 50 mM HEPES-KOH, pH 7.5; 200 mM KCl; 25 mM 
DTT; 50 mM MgCl2; 20 nM ribozyme and 10 nM substrate.  The ribozyme and 
substrate strands were prepared as described above.  The reaction took place at 37 °C 
unless otherwise noted.  Steady-state FRET measurements of the glmS ribozyme doubly 
labeled with fluorescein and tetramethylrhodamine were performed on a AB2 
spectrofluorometer.  Fluorescein was excited at 490 nm (4 nm bandwidth), and 
fluorescence emission was recorded simultaneously at the fluorescein (520 nm, 8 nm 
bandwidth) and tetramethylrhodamine (585 nm, 8 nm bandwidth) wavelengths, by 
shifting the emission monochromator back and forth. A FRET ratio was calculated as 
F585/F520.  Stock solutions (135 L) for final concentrations as listed for the reactions 
above were annealed as described and transferred to a 150 L cuvette kept at appropriate 
temperature by a circulating water bath.  After 1 minute, GlcN6P was added to an 
appropriate final concentration in 15 L to initiate the reaction and mixed manually in 
about 5 s. 
FRET multiple-turnover cleavage experiments.  Multiple-turnover cleavage 
experiments were prepared and monitored as the single-turnover assay above, except 
ribozyme and substrate strands were 10 nM and 100 nM, respectively.  The reactions 
took place at the temperatures indicated in Results and Discussion. To cycle the 
temperature of the sample in the cuvette, two water baths were maintained at appropriate 
temperatures and their connecting hoses manually switched. 
High-speed CE cleavage assays.  Single-turnover CE experiments were 
performed under the same reaction conditions as the single-turnover FRET experiments, 
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except the ribozyme and substrate concentrations were 400 nM and 200 nM, respectively, 
and they contained 25 nM rhodamine 110 as an internal standard.  Stock solutions were 
prepared, annealed as described above, and reactions started by adding 45 L stock 
solution to pre-aliquoted 5 L GlcN6P for appropriate final concentrations.   They were 
incubated at 37 °C in a thermal cycler for 10 min or 30 s, as appropriate, then quenched 
with 10 L EDTA, pH 8 to a final concentration of 100 mM EDTA and stored on ice 
until analysis.  Multiple-turnover samples were performed under the same conditions 
except with 20 nM ribozyme and 200 nM substrate.  They were either incubated at 50 
°C or cycled between 42 °C and 60 °C, as described in Results and Discussion. 
A schematic drawing of the flow-gated high-speed CE-LIF instrument used for 
kinetics analysis is illustrated in Figure 2-1.  An unmodified fused silica capillary (10 
µm inner diameter, 360 µm outer diameter, total length = 7.5 cm, inlet to detector length 
= 3.8 cm) was used as the separation capillary.  GlcN6P was delivered to a pressurized 
sample container containing reaction mixture at a flow rate of 5 µl/s for 2 s by pressure.  
A 5 × 2 mm microbar in the sample vial together with the stir plate underneath allowed 
the sample to be mixed immediately.  After mixing, the sample was delivered to the 
flow gate at a rate of 0.8 µl/s by pressure.  Samples were then introduced onto the 
capillary by electrokinetic injection via a flow gate interface at 2 kV for 1 s and separated 
at 15 kV.  The total delay time between addition of unlabeled peptide and the collection 
of the first electropherogram was 7 s, including sample delivery time, high voltage 
ramping time and injection time.  Electropherograms were collected every 12.5 s.  
Tris-glycine-potassium buffer (25 mM tris(hydroxyamino)methane, 192 mM glycine, 5 
mM K2HPO4) was continuously delivered to the flow gate at a rate of 1.5 ml/min by a 
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Series I HPLC pump (LabAlliance, Fisher Scientific, Pittsburgh, PA). For CE assays, the 
sample mixing system was not used, the separation capillary was 25 µm inner diameter, 
360 µm outer diameter, total length = 7 cm, inlet to detector length = 3.5 cm, and samples 
were introduced onto the capillary by electrokinetic injection via a flow gate interface at 




Figure 2-1. Schematic drawing of the high speed CE instrument used for kinetics studies.  For the CE assays, 
the sample mixing system was not used.  Figure adapted from source.87 
The peak heights were obtained from the electropherograms using Cutter
88
 and 
normalized complex peak height (product peak height divided by sum of peak heights of 
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product and substrate) was plotted versus time to extract kobs by fitting the curve into one-
component exponential decay function (kinetics) or against GlcN6P concentration for the 
assays.   
 
Results and Discussion 
Single-Turnover FRET Assay. The cleavage reaction of a minimal, trans-
cleaving glmS ribozyme (Figure 2-2) induced by GlcN6P was monitored by FRET, as has 
previously been demonstrated.
51
  The substrate strand of the glmS ribozyme was labeled 
on the 5‟ end with fluorescein as the FRET donor and on the 3‟ end with rhodamine as 







Figure 2-2. The glmS ribozyme minimal structure and fluorophore labels.  The doubly labeled construct is used 
for FRET studies, while the substrate strand is labeled with only the donor fluorophore, fluorescein, for CE 
studies.  The open arrow indicates the cleavage site.51  
In the intact ribozyme-substrate complex, the fluorophores are sufficiently close 
(~52 Å) to allow efficient energy transfer from the excited donor to the acceptor, 
resulting in emission at the wavelength characteristic of the acceptor.  After cleavage, 
the 5‟-product dissociates from the ribozyme-substrate complex, so that the fluorescein 
emission increases and the FRET ratio decreases (Figure 2-3A).  There is also a small 
increase in acceptor signal, which we attribute to donor signal detected in the acceptor 
channel.  The cleavage rate was determined by fitting the FRET decrease as well as the 
donor fluorescence increase upon GlcN6P addition with single exponential decay and 
association curves, respectively.  The measured rate constants were in good agreement, 




0.0294 ± 0.0006 s
-1
 for the FRET and donor fluorescence fits, respectively.  In view of 
their similarity, for all further work the donor signal was used due to its higher signal to 
noise ratio (Figure 2-3B). 
 
.   
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Figure 2-3. A. 100 M GlcN6P detection by FRET measured in 50 mM HEPES-KOH, pH 7.5, 200 mM KCl, 25 
mM DTT, 50 mM MgCl2, 20 nM glmS ribozyme, 10 nM doubly labeled substrate, 37 °C.  B. Fit of donor 
fluorescence (single exponential association) for determination of cleavage rate.  
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Previous reports on using this aptazyme used 50 mM HEPES-KOH, pH 7.5; 200 
mM KCl; and 10 mM MgCl2 as the reaction buffer.  As buffer conditions can have a 
significant effect on assay kinetics, we varied several parameters to ensure adequate 
cleavage rates for the assay.  For this study, 50 mM HEPES-KOH, 200 mM KCl, and 25 
mM DTT were used as the background electrolytes and 10 nM substrate was used.    
Other parameters were varied sequentially over the following ranges as follows: pH 7.5 
or 8.5, MgCl2 concentration from 10-50 mM, ribozyme concentration from 20-50 nM, 
and temperature from 25-60 °C.  Within these limits, the best assay sensitivity was 
achieved with pH 7.5, 50 mM MgCl2, 20 nM glmS ribozyme, and reaction temperature at 
37 °C.  The ribozyme is inactive at 60 °C.  These conditions were used for subsequent 
assays. 
Cleavage rates were measured by FRET over a range of concentrations of 
GlcN6P.  As shown by the calibration curves in Figure 2-4, the rate of cleavage 
increases linearly with GlcN6P up to 500 µM analyte with an R
2
 value of 0.999.  The 
limit of detection (LOD) is 0.8 M, which was calculated as 3 times the standard 
deviation of the blank divided by the slope of the calibration curve.  At high 
concentrations of GlcN6P, above the linear dynamic range, the rate of cleavage is very 
fast, leading to high standard deviations, at least in part as a result of the length of time 




Figure 2-4. FRET calibration curve.  Response is based on rate of cleavage reaction, which increases linearly 
up to 500 M with an R2 value of 0.999.  The limit of detection is 0.8 M. 
Single-Turnover CE Assay.  We next used free-solution CE-LIF to monitor the 
single-turnover reaction of our glmS ribozyme with a 5‟ fluorescein labeled substrate.  
The reaction mixture was sampled every 12.5 seconds and analyzed by CE-LIF.  The 
resulting electropherograms have three peaks: internal standard (rhodamine 110), 
ribozyme-substrate complex, and cleavage product (Figure 2-5A).  The progress of the 
reaction was monitored by observing the decreasing height of the ribozyme-substrate 
complex peak as well as the increasing peak height of the cleavage product.  For 
quantitative analysis, these two peak heights were normalized by dividing by their sum.  
The reaction rate constant was obtained by plotting the normalized peak heights versus 
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time and fitting the data with single exponential decay and association curves (Figure 2-
5B).  The reaction rate constant in the presence of 500 µM GlcN6P was determined to 
be 0.0052 ± 0.0002 s
-1
, in good agreement with the rate of 0.00603 ± 0.00008 s
-1
 
determined by FRET for the same GlcN6P concentration.  In response to 5 mM 
GlcN6P, the rate constant is measured to be 0.029 ± 0.001 s
-1
 by CE and 0.028 ± 0.001 s
-1
 
by FRET.  These results demonstrate that the rapid CE separation allows for kinetic 




Figure 2-5. 500 μM GlcN6P detection by CE measured in 50 mM HEPES-KOH, pH 7.5, 200 mM KCl, 25 mM 
DTT, 20 mM MgCl2, 500 nM singly labeled substrate, 1 M glmS ribozyme, 25 °C.  A. Electropherograms of 
ribozyme cleavage.  B. Fit of ribozyme cleavage rate as measured by CE, which is in good agreement with rate 
determined by FRET.  k = 0.0052 ± 0.0002 s-1.    
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We next evaluated the use of CE-LIF as a readout for an GlcN6P assay by 
detecting the extent of reaction with a range of concentrations of GlcN6P using solution 
conditions optimized by FRET.  For the CE assay, the cleavage reaction was started and 
ten minutes later the sample was injected into the CE for separation and detection.  The 
separation was completed in less than ten seconds, eliminating the need to quench the 
cleavage reaction.  Thus, the use of a separation step to the assay allowed normalization 
of a single time point measurement, simplifying the assay for GlcN6P.  Normalizing the 
data in the same way as described for determining the rate of reaction by CE provided 
information about the fraction of substrate cleaved, from which a calibration was 
obtained.  The linear dynamic range for this calibration extends from 0.5 to 10 µM 
(Figure 2-6).   
After a 10 min reaction at concentrations of GlcN6P over 10 µM, the reaction has 
proceeded to completion.  Therefore, to extend the dynamic range to GlcN6P 
concentrations above 10 µM, the reaction mixture was injected at thirty seconds instead 
of ten minutes.  At this reaction time, concentrations of GlcN6P below 10 µM are 
indistinguishable due to the very small progression of the cleavage reaction, but 
concentrations greater than 10 µM are easily distinguished, resulting in a linear dynamic 
range from 10 to 100 µM (Figure 2-6).  With the two calibrations, the LDR for our free-
solution CE assay is 0.5 to 100 µM GlcN6P, with an R
2
 of 0.998.  The detection limit is 
0.5 M. The single-turnover assays demonstrate the potential of the glmS ribozyme in an 





Figure 2-6. CE calibration. Left and bottom axes and closed symbols represent low concentration GlcN6P 
samples.  Right and top axes and open symbols represent high concentration GlcN6P samples.  Single-
turnover samples are represented by blue squares, multiple-turnover (50 °C) by red circles, and multiple-
turnover (cycled) by green triangles. 
Both the FRET and CE methods appear to be useful for monitoring the reaction.  
For kinetic measurements, the FRET reaction achieves a 1 s temporal resolution 
compared to the 12 s possible by the CE-LIF method.  As an assay, the FRET method 
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has a wider dynamic range; primarily because it is based on the kinetic data rather than a 
fixed time point like the CE-LIF method.  For the same reason, the CE method was 
much faster, with each sample taking only seconds to analyze after the cleavage reaction, 
rather than minutes or hours.  The CE method offered the advantage of detection of two 
separate peaks for the cleaved and uncleaved substrate, which allowed for normalization 
of the signal at a single time point.  This kind of normalization is not achievable by 
FRET.  This offers less noise and a lower LOD and is less prone to errors due to non-
ribozyme based changes in total fluorescence.   The LOD is likely determined by the 
affinity of the effector for the ribozyme, which has an apparent Kd of 200 M,
38
 as well 
as by the background cleavage observed in the absence of GlcN6P.  The CE method 
uses less analyte with sample volumes as low as 10 µL compared to 150 µL FRET 
samples.  The CE method uses singly-labeled substrate, whereas the substrate for FRET 
was doubly labeled.  The temporal resolution of the FRET method allowed for constant 
observation of the samples, which was crucial for gaining an understanding of the 
multiple-turnover reaction.  CE could then be used for the single time point, multiple-
turnover cleavage assay.  
Multiple-Turnover FRET Assay. To further improve the sensitivity of GlcN6P 
detection by the glmS ribozyme, multiple-turnover reaction conditions were investigated.   
Under multiple-turnover conditions, excess substrate is provided, allowing the ribozyme 
strand to cleave multiple substrate molecules as illustrated in Figure 2-7A (inset).  In 
principle, this approach would allow generation of more signal for a given effector 
molecule.   
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In our initial experiments we used 10 nM glmS ribozyme and 100 nM substrate 
and FRET was used to monitor the progress of the reaction.  At 25 °C, the increase in 
donor signal is no greater than the increase observed under single-turnover conditions, 
indicating that only one set of substrate molecules is cleaved.  These results suggested 
that the 3‟-product, which binds the ribozyme with the same number of base pairs as the 
uncleaved substrate, did not dissociate from the ribozyme rapidly enough to allow 
efficient multiple-turnover events. We hypothesized that elevated temperatures may 
accelerate 3‟-product dissociation and, thus, substrate turnover.  Indeed, as the 
temperature of the cleavage reaction was increased, the extent of cleavage increased, 
which is evident from the increase in donor fluorescence (Figure 2-7A).  At 
temperatures up to 50 
o
C, two phases of cleavage are observed, a slow phase and a fast 
phase.  At 50 °C, the rate of cleavage becomes linear with a slope in between the former 
slow and fast phases.  These observations suggest that the first phase reports on the first 
turnover where the reaction is rate-limited by substrate cleavage, while the second phase 
reflects subsequent turnovers where slow 3‟-product dissociation becomes rate-limiting.  
Examining the slope of the linear portion of each the first and second phases further 
supports this conclusion (Figure 2-7B).  In the first phase, the observed rate constant 
increases with increasing temperature to 37 °C, then decreases to 50 °C.  This suggests 
that the reaction is accelerated with increasing temperature until the rate of substrate 
association becomes limiting.  By contrast, in the second phase the observed rate 
constant continually increases to its maximum at 50 °C.  We think this can be explained 
by increasing rate of substrate dissociation. At this temperature, a single rate constant is 
observed over a broader fluorescence signal range, consistent with multiple substrate 
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turnovers.  The ribozyme is inactive at 60 °C.  We therefore chose 50 °C, where the 
ribozyme turns over multiple substrate strands with reasonable efficiency and thus 
amplifies the signal over that achieved under single-turnover conditions after about ten 
minutes (Figure 2-7A).  The length of time required to achieve such signal amplification 
is dependent on the concentration of GlcN6P. 
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Figure 2-7. Comparison of three constructs of Fyn binding to Fluor-Fyn peptide.  Sample contained 500 nM 
Fyn-SH2-SH3 (trace 1) or GST-Fyn-SH2 (trace 2) or GST-Fyn-SH2-SH3 (trace 3), 200 nM Fluor-Fyn peptide  
and 10 nM rhodamine 110.   Separation conditions were the same as in Figure 3-4. 
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These results suggested the possibility that a temperature program could be used 
to achieve better signal amplification.  Specifically, we developed a two-temperature 
program that used an elevated temperature (60 °C) to dissociate the substrate-ribozyme 
pair, and then lowered the temperature to allow reannealing, reformation of uncleaved 
substrate-ribozyme-effector complex, and cleavage reaction.   We varied the 
denaturation temperatures from 50 °C to 60 °C (for 30 s) and the reaction time at 42 °C 
from 3 to 20 min while monitoring the reaction by FRET.  The best conditions (i.e., 
most amplification) were found with 42 °C for 10 min followed by a 30 s pulse to 60 °C.  
This process of cycling between reaction and dissociation temperatures resulted in about 
4-fold signal amplification over fixed temperature at 42 °C and 2-fold at 50 °C after 40 
min, as illustrated in Figure 2-8.   This method is limited by binding of the 5‟ cleavage 
product, which is fully complementary to the ribozyme, and thus competes with 
uncleaved substrate for binding.  An alternate way to achieve multiple turnover events 







Figure 2-8. Multiple-turnover FRET with cycling.  Signal amplification is achieved by increasing the 
temperature to 50 °C.  Further amplification is observed when the temperature is cycled between 42 °C and 
60 °C.  The donor fluorescence increases with cleavage until the temperature is raised to 60 °C, which lowers 
the quantum yield of the fluorophore.  When the temperature is returned to 42 °C, donor fluorescence 
increases as a new set of substrates bind and are cleaved. 
Multiple-Turnover CE Assay. The conditions for the multiple-turnover reaction 
that were optimized by FRET were used in a CE assay.  In this assay, ribozyme-
substrate samples were either incubated at 50 °C or temperature cycled between 42 °C 
and 60 °C for 10 min and 30 s, respectively, over a total time of 3.5 hours.  High 
GlcN6P concentration samples were incubated for 5 min either at 50 °C or temperature 
cycled between 42 °C and 60 °C for 1.5 min and 30 s, respectively.  The slopes of the 
multiple turnover calibration curves are steeper than that of the single-turnover samples 
by 2-fold for the 50 °C assay and 13-fold for the cycled assay, indicating increased 
sensitivity (Figure 2-6).  The LDR‟s for these CE based assays are 0.5 to 100 µM (R
2
 
for 50 °C is 0.995 and 0.999 for cycled), which is the same as the range for the single-
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turnover assay, but the detection limit is improved to 0.1 M for the 50 °C assay and 0.05 
M for the cycled assay.   
 
Conclusions 
This work demonstrates the use of FRET and CE-LIF for detection of the 
cleavage rate of the glmS ribozyme in response to GlcN6P.  For kinetic measurements, 
the FRET reaction achieves a 1 s temporal resolution compared to the 12 s possible by 
the CE method.  The two techniques are in good agreement for determination of the rate 
constant.  We report the use of free-solution CE-LIF for the separation of RNA 
molecules.  These two techniques were used to detect GlcN6P as low as high nanomolar 
concentrations up to high micromolar concentrations under single-turnover conditions, 
where FRET has a wider dynamic range, because it is based on kinetic rather than 
fraction cleaved data.  For single turnover assays, the methods have similar detection 
limits.  Using multiple-turnover conditions, CE was used to detect GlcN6P with greater 
sensitivity over the same range of concentrations.  Overall, CE was faster and required 
smaller sample volumes than FRET.  These proof of principle experiments demonstrate 
the potential of ribozymes for use as recognition elements in FRET and CE based assays. 
Future work for these proof-of-principle assays using the glmS ribozyme could 
involve the study of development of insulin resistance in cells.  GlcN6P is involved in 
the hexosamine biosynthetic pathway, whose major end product, UDP-N-acetyl-
glucosamine, serves as a substrate for glycosylation reactions.  One to three percent of 
cellular glucose that is converted to fructose-6-phosphate enters this pathway, and 
increased flux into this pathway has been shown to result in impaired ability of insulin to 
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stimulate glucose uptake.  The glmS ribozyme is also interesting due to its role in the 
manufacture of GlcN6P, which is a precursor of uridine 5‟-diphospho-N-acetyl-D-
glucosamine, a molecules that is essential for cell wall biosynthesis in Bacillus subtilis 
and other bacteria.
89
  Thus, future work could involve high-throughput screening for 
potential drug candidates, as repression of the glmS gene would reduce the cellular 
concentration of GlcN6P, ultimately disrupting cell wall biosynthesis.  The CE assay is 
particularly amenable to a high-throughput approach as CE can be performed in parallel.  
With the current availability of aptazymes that are specific for a variety of target 
molecules, as well as the ability to engineer or select additional aptazymes, the 
development of aptazyme-based assays for the detection of many other biologically 
relevant molecules is an active area of research.  The speed and ability to multiplex CE 
assays either by using multiple capillaries in parallel or by separating the products of 
multiple reactions in one capillary make CE an attractive mechanism for detecting 





CHARACTERIZATION OF ENGINEERED APTAZYMES FOR USE IN DETECTION 
OF CAMP AND ATP 
Introduction 
Nucleic acids have been demonstrated to function in a variety of different 
contexts, from storing genetic information to catalyzing biochemical reactions.  
Relatively recently, they have been demonstrated to be able to catalyze chemical 
reactions under allosteric control, that is, in response to effector binding.
17, 27, 42, 50
  Thus, 
they can serve as both recognition and transduction elements in bioanalytical assays.  In 
addition, the ease of synthesis and their temperature stability make these aptazymes 
potentially interesting molecules for affinity assays.  There has been some investigation 
into their analytical potential,
17, 27, 42, 50
 but there is still much work to be done.  We are 
interested in developing multiplexed assays using aptazymes for recognition and 
transduction elements, thus we set out to characterize three known aptazymes for 
potential use in such an assay. 
The potential of aptazymes lies in the ability to design or select them to be 
responsive to a wide variety of different analytes.  To date, they have been demonstrated 
to cleave in response to oligonucleotides, small molecules, proteins, and metal ions.
17, 27, 
42, 50
  In addition to developing new aptazymes, a complete characterization of existing 
ones can lend insight into parameters that will be desirable for precise detection and 
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quantification of molecules.  These parameters can help to inform the selection or 
design conditions for new aptazymes.    
Ideally, aptazymes would be specifically activated by only one analyte and not 
analogs of that molecule.  They would have low background reactivity (typically in 
RNA backbone cleavage) in the absence of effector.  They would be trans-cleaving, so 
that they could function in a multiple turnover capacity to cleave multiple substrates per 
aptazyme, thus amplifying the signal.  They would have a wide dynamic range.  
Natural self-cleaving ribozymes catalyze RNA transesterification with rate constants that 
are near 1 min
-1
 under physiological conditions.  Aptazymes typically cleave at a much 
slower rate, especially in their trans-cleaving forms.   
Two aptazymes that we will consider herein were developed for ATP and cAMP 
effectors.  The Breaker group designed an aptazyme for ATP by coupling a 
corresponding RNA aptamer to the hammerhead ribozyme via a variable communication 
domain.
32
  The ATP aptamer has a Kd of 0.7 M.  The aptamer also binds to adenosine 
and AMP with similar affinities.
61
  The same group used in vitro selection to develop 
aptazymes that respond to cAMP and cGMP.
37
  The selection scheme applied selective 
pressure to a hammerhead ribozyme that was coupled to a 25-nucleotide random 
sequence domain via a known communication domain and involved both negative and 
positive selection steps.  The apparent dissociation constants for these aptazymes were 
determined by measuring the half-maximal cleavage activity.  For the cGMP aptazyme, 
the apparent Kd is 200 M.  The apparent Kd for the cAMP aptazyme is 500 M.
38
  
The high apparent dissociation constants are expected to prevent assays using these 
aptazymes from rivaling LOD‟s obtained in current assays. 
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Assays for ATP as the energy currency of the cell can be used to determine cell 
viability and to study cellular processes in which it is involved, which include many 
biosynthetic reactions and signal transduction pathways.  Detection of cAMP as a 
second messenger can be used to study signal transduction and enzyme activity.  
Commercial kits based on radioactivity, fluorescence, and bioluminescence are available 
for the detection of ATP, cAMP, and cGMP with detection limits that are in the pM 
range.  With the current stage of development of aptazymes, it is not realistic to assume 
that they will offer similar LOD‟s.  Perhaps the most interesting characteristic of an 
aptazyme system is the ability to design or develop aptazymes for a wide range of 
interesting effectors, which could include analytes that are currently difficult to detect.  
For now, these serve as proof of principle assays that demonstrate the potential of this 
interesting group of molecules in analyte detection. 
We describe the characterization of two trans-cleaving aptazymes that we have 
designed from the cis-cleaving aptazymes for cAMP and ATP, described above.  We 
consider their rate of cleavage, pursue optimization of the cleavage conditions, and 
compatibility for multiplexed detection.  These initial studies were done with gel 
electrophoresis, which has been the workhorse for detection of ribozyme cleavage, and 
can offer parallel detection by separating many samples on one gel.  We use 
fluorescently labeled RNA substrates, eliminating the need for radiochemicals.  
Fluorescent labeling is also more practical for real assays by allowing longer storage 





Chemicals.  Unless stated otherwise, all chemicals were purchased from Sigma-
Aldrich Co. (St. Louis, MO).  DNA templates were purchased from Invitrogen 
(Carlsbad, CA).  RNA substrates were purchased from W. M. Keck Foundation (New 
Haven, CT).  See Figure 3-1 for sequences.  All solutions were prepared with 
deionized water from an E-Pure water purification system (Barnstead International Co., 
Dubuque, IA).  T7 RNA polymerase was expressed and purified according to the 
protocol in Appendix B.   
Preparation of aptazymes.  Complementary DNA strands were annealed at 70 
°C for 2 min and cooled to room temperature over 5 min.  RNA was transcribed from 
this DNA template at 37 °C in an overnight reaction using the following reagent 
concentrations: 100 nM DNA templates; 2 mM NTP mixture; 120 mM HEPES-KOH, pH 
7.5; 30 mM MgCl2; 2 mM spermidine; 40 mM DTT; 0.04% triton X-100; 0.005 U/µL; 
0.1 mg/mL T7 RNA polymerase; and 8% polyethylene glycol.  The reaction was 
purified on a 10 % polyacrylamide gel and eluted overnight in water, then chloroform 
extracted and ethanol precipitated.  RNA substrates were deprotected according to the 
manufacturer protocol, precipitated with butanol, purified by 15 % PAGE, eluted by 
tumbling overnight in water, chloroform extracted, ethanol precipitated, and HPLC 
purified.  The concentrations of nucleic acid samples were determined using their 
absorbance at 260 nm. 
Cleavage reactions.  Cleavage reactions were performed under the following 
conditions unless otherwise noted: 150 nM aptazyme; 75 nM substrate; 50 mM Tris-HCl, 
pH 7.5; 50 mM MgCl2, and 25 mM DTT.  The ribozyme and substrate strands were 
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annealed at 90 °C for two min, then cooled to room temperature over 5 min.  The 
reaction took place at room temperature for 2 hr, unless otherwise noted.  Reactions 
were separated by 20 % PAGE at 20 W for 2 hr and analyzed on a Typhoon Trio (GE 
Healthcare, Piscataway, NJ) using fluorescence detection with excitation at 488 nm and 
detection at 530 nm and the platen focal depth setting, with the gel placed directly on the 
glass platen.  Gel scans were analyzed with ImageQuant, dividing the intensity of the 
product band by the sum of the intensities of the product and substrate bands. 
 
Results and Discussion 
Design of trans-cleaving aptazymes.  Based on cis-cleaving constructs of 
aptazymes for cAMP, cGMP, and ATP,
32, 37, 38
 we designed trans-cleaving aptazymes by 
eliminating the loop of stem III (Figure 3-1A and B).  We also weakened stem I and 
thus product (and substrate) binding by replacing two G-C base pairs with A-U pairs to 
promote product dissociation.  Finally, two overhanging (unpaired) G‟s were added at 
the 5‟-end for efficient transcription.  We designed three substrates for these aptazymes, 
with different 3‟ ends, for use in possible multiplexed assays, in which the ability to 
separate 3‟ cleavage products would be necessary (Chapter 4).  All substrates were 
labeled with fluorescein on the 3‟ end (Figure 3-1B-D).    
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Figure 3-1. Design of trans-cleaving aptazymes. Aptazymes are shown in black and substrates are shown in red.  
Arrow indicates cleavage site.  Substrates are labeled with fluorescein on the 5’ end.  A. cis-cleaving 
hammerhead module. B. ATP aptazyme. C. cAMP aptazyme. D. cGMP aptazyme. 
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Cleavage of trans-cleaving aptazymes.  In initial experiments, we tested the 
capability of these constructs to catalyze self-cleavage in response to binding of their 
respective effector molecules.  Due to the method of design of the aptazymes, that is, all 
used the same hammerhead ribozyme, the binding regions of the substrate molecules 
were all identical and, thus, interchangeable.  As shown in Figure 3-2, the aptazymes for 
cAMP and ATP cleaved substrates A and B in response to activation by their respective 
effectors, but the aptazyme for cGMP did not effectively cleave any of the three 
substrates.  None of the aptazymes cleaved substrate C very well, though the ATP 
aptazyme did show some activation with ATP.  The cAMP aptazyme cleaved 26% of 
substrate A when activated and 11% in the absence of effector, compared to 18% and 7% 
of substrate B.  The ATP ribozyme, on the other hand, activated both substrates equally 
well.  Therefore, we proceeded to characterize the cAMP ribozyme with substrate A and 












Figure 3-2. Cleavage activity of ATP, cAMP, and cGMP aptazymes with each of three substrates.  Plus 
indicates presence of 1 mM effector and minus indicates no effector present.     
Characterization of trans-cleaving aptazymes.  Aptazyme cleavage is known 
to be dependent on concentration of divalent and monovalent ions, so we tested cleavage 
efficiency under a variety of conditions for both aptazymes.  Of the conditions tested, 
the cAMP ribozyme cleaves best at 100 mM MgCl2 and no KCl, with 28% cleavage in 
response to effector and 9% in the absence of effector (Figure 3-3A and C).  The ATP 
aptazyme, on the other hand, showed the greatest enhancement in cleavage at 50 mM 
MgCl2 and no KCl, with 48% and 30% cleavage with and without effector (Figure 3-3B 
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and D).  At higher concentrations of MgCl2, background cleavage is increased while 
ATP induced cleavage is not.  This highlights two important areas that could be 
addressed in the aptazyme selection process when designing aptazymes to be compatible 
for a multiplex format.  The incompatibility of these aptazymes as a result of their 
different metal ion dependencies could be addressed by simultaneous selection of 
aptazymes for use in analytical assays.  Additionally, the high background cleavage of 
the ATP aptazyme might be decreased by adding negative selection steps to remove 
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Figure 3-3. Characterization of ATP and cAMP aptazymes.  A. cAMP aptazyme cleavage at various 
concentrations of MgCl2. B. ATP aptazyme cleavage at various concentrations of MgCl2.  C. cAMP aptazyme 
cleavage, KCl characterization.  D. ATP aptazyme cleavage, KCl characterization.  
With the long-term goal of multiplexing these aptazymes, we considered the 
compatibility of their reaction conditions.  It seemed that the best compromise for both 
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ribozymes was to use 50 mM MgCl2 and no KCl, so we tried assays for their respective 
effectors.  The resulting calibration curves demonstrated that while low M 
concentrations of effector could be discriminated by the ATP aptazyme, they could not 
by the cAMP aptazyme.  At 100 mM MgCl2, however, the cAMP aptazyme could detect 
low M concentrations of cAMP (Figure 3-4). 
 
Figure 3-4. Calibration of ATP and cAMP aptazymes.  ATP aptazyme cleaves effectively at 50 mM MgCl2.  
cAMP aptazyme is better at 100 mM MgCl2.     
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Another important factor in analyte detection is specificity.  We therefore tested 
the cross-reactivity of the aptazymes with similar compounds.  We found that the cAMP 
aptazyme is not activated by any of the following molecules: ATP, ADP, AMP, or cGMP 
(Figure 3-5A).  In their original aptamer selection, the Breaker group involved many 
negative selection steps in the evolution of the cAMP aptazyme.
37
  The ATP aptazyme, 
which was generated by a rational design approach with no negative selection steps,
32
 is 
by contrast activated by ADP, AMP, and cAMP, though not by cGMP (Figure 3-5B).  
These results are consistent with previous work done by the Szostak group, which shows 
that the ATP aptamer binds to adenosine and AMP with similar affinities as ATP.
61
  
These results suggest that a careful selection strategy can result in a more specific 
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Figure 3-5. Specificity of cAMP and ATP aptazymes.  A. cAMP aptazyme is not activated by ATP, ADP, AMP, 
or cGMP.  B. ATP aptazyme is activated by ADP, AMP, and cAMP, but not by cGMP.   
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To further consider the ATP aptazyme, we compared its activation by ATP and 
AMP (Figure 3-6).  From these data, we can see that the ATP aptazyme is activated by 
AMP to nearly the same extent as with ATP.  A linear regression of the linear portion of 
the calibration, which is from 0 M to 10 M for both effectors (R
2
 is 0.999 for ATP and 
0.993 for AMP), allows the calculation of the LOD‟s, which were 3 M and 2 M for 
ATP and AMP, respectively.  These results correspond with the demonstrated affinity of 
the ATP aptamer for other adenosine-containing molecules.
61
  Solution structures of the 
ATP aptamer complexed to AMP reveal that the nucleotide binds in an internal loop.  
The loop forms a binding pocket which surrounds the AMP molecule, with only the C8 
and N7 atoms and the phosphate group exposed to solution.  The AMP molecule 
hydrogen bonds to a G nucleotide.
90, 91
  These results suggest that affinity for adenosine 
is responsible for the broad response of the ATP aptazyme.  To develop an aptazyme 
that would be effective in an analytical assay, the selection conditions for the aptazyme 
could be improved to include negative selection steps for analytes that are structurally 





Figure 3-6. ATP aptazyme activation by ATP and AMP.  AMP activates aptazyme to nearly the same extent as 




Aptazymes can be analytically useful molecules as they function both as 
recognition and transduction elements and can be designed or selected to respond to a 
wide variety of different molecules.  We investigated the cAMP and ATP aptazymes to 
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evaluate their potential for use in bioanalytical assays.  A successful assay will involve 
aptazymes that are sensitive, specific, and compatible.  The cAMP aptazyme is 
specifically activated by cAMP, is sensitive to low M concentrations of cAMP, but is 
not compatible with the ATP aptazyme, as both buffer conditions and time required for 
reaction differ.  The ATP aptazyme is sensitive to low M concentrations of ATP, but 
activated by a variety of similar molecules including ADP, AMP, and cAMP, which is 
consistent with data that show that the ATP aptamer binds to adenosine and AMP with 
similar affinities as ATP.
61
  These results suggest that design of selection conditions for 
an aptazyme intended to be used in bioanalytical assays could be optimized with these 
desirable characteristics in mind.  In particular, aptazymes for use in a multiplex assay 
could be selected in the same buffer conditions for the same length of time as will be 
used in the assay.  Further, negative selection steps may be necessary to avoid high 




MULTIPLEXED DETECTION OF SMALL MOLECULES BY GEL 
ELECTROPHORESIS USING APTAZYMES 
 
Introduction 
The ability to simultaneously detect analytes in one assay holds great potential for 
rapid analysis necessary for detection and characterization of disease states, enzyme 
function and various high-throughput screening assays.  There is potential for use of 
multiplexed assays in metabolomics and as a clinical panel.  Immunoassays have been 
used for multiplexed detection,
92
 as have aptazymes, which are being studied as potential 
replacements for antibodies in some assay formats.  In particular, aptazymes have been 
arranged into arrays for multiplexed detection.
42, 93
  Adding a separation step to an 
aptazyme assay would eliminate the need for immobilization of the aptazymes to a 
surface, resulting in an easily transferable assay. Further, it could reduce the sample 
requirement, because in an array the sample must cover the entire surface, whereas less is 
required for many separations.  In CGE, for example, nL volumes are injected.  On the 
other hand, with a separation, it is necessary to have physically distinguishable cleavage 
products, which may require redesign of the catalytic domain if the same module is used 
for multiple aptazymes, whereas in an array format the aptazymes are distinguished 
spatially.  In this chapter, we aimed to develop a multiplexed assay for the aptazymes 
characterized in Chapters 2 and 3. 
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The potential of aptazymes lies in the ability to design or select them to be 
responsive to a wide variety of different analytes.  To date, they have been demonstrated 
to cleave in response to oligonucleotides, small molecules, proteins, and metal ions. 
17, 27, 
42, 50
  For use in a multiplexed assay, each aptazyme would need to be specifically 
activated by only a single analyte and not related ones.  Furthermore, they need to 
cleave at compatible rates under the same conditions have cleavage products that can be 
distinguished by the analytical method used.  For example, products of different lengths 
could be used with detection by PAGE, CE, or fluorescence anisotropy or products with 
different fluorescent labels could be used with fluorescence detection. 
Three aptazymes that we will consider herein included one naturally occurring 
aptazyme, the glmS ribozyme; one rationally designed aptazyme, the ATP aptazyme; and 
one in vitro selected aptazyme, the cAMP aptazyme.
28, 32, 37
  Assays for GlcN6P with 
detection by the glmS ribozyme could involve the study of development of insulin 
resistance in cells, as increased GlcN6P flux into the hexosamine pathway has been 
shown to result in impaired ability of insulin to stimulate glucose uptake.
56
  Assays for 
ATP can be used to determine cell viability and to study cellular processes in which ATP 
is involved, which include biosynthetic reactions and signal transduction pathways.  
Detection of cAMP can be used to study signal transduction and enzyme activity.  We 
set out to pursue proof-of-principle studies to demonstrate the potential of aptazymes in 
multiplexed analyte detection. 
We describe the multiplexing of two pairs of trans-cleaving aptazymes, for ATP 
and cAMP as well as for GlcN6P and ATP.  We consider their rates of cleavage, an 
optimization of their cleavage conditions, and their compatibility for multiplexed 
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detection.  These initial studies were done with gel electrophoresis, which has been the 
workhorse for detection of ribozyme cleavage, and can offer parallel detection by 
separating many samples on one gel.  We use fluorescently labeled RNA, eliminating 
the need for radiochemicals. 
   
Experimental Section 
Chemicals.  Unless stated otherwise, all chemicals were purchased from Sigma-
Aldrich Co. (St. Louis, MO).  DNA templates were purchased from Invitrogen 
(Carlsbad, CA).  RNA substrates were purchased from W. M. Keck Foundation (New 
Haven, CT).  See Figures 2-1 and 4-1 for sequences.  All solutions were prepared with 
deionized water from an E-Pure water purification system (Barnstead International Co., 
Dubuque, IA).  T7 RNA polymerase was expressed and purified according to the 
protocol in Appendix B.   
Preparation of aptazymes.  Complementary DNA strands were annealed at 70 
°C for 2 min and cooled to room temperature over 5 min.  RNA was transcribed from 
this DNA template at 37 °C in an overnight reaction using the following reagent 
concentrations: 100 nM DNA templates; 2 mM NTP mixture; 120 mM HEPES-KOH, pH 
7.5; 30 mM MgCl2; 2 mM spermidine; 40 mM DTT; 0.04% triton X-100; 0.005 U/µL; 
0.1 mg/mL T7 RNA polymerase; and 8% polyethylene glycol.  The reaction was 
purified on a 10 % polyacrylamide gel and eluted overnight in water, then chloroform 
extracted and ethanol precipitated.  RNA substrates were deprotected according to the 
manufacturer protocol, precipitated with butanol, purified by 15 % PAGE, eluted by 
tumbling overnight in water, chloroform extracted, ethanol precipitated, and HPLC 
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purified.  The concentrations of nucleic acid samples were determined using their 
absorbance at 260 nm. 
Cleavage reactions.  ATP and cAMP aptazyme cleavage reactions were 
performed under the following conditions: 150 nM aptazyme; 75 nM substrate; 50 mM 
Tris-HCl, pH 7.5; 50 mM MgCl2, and 25 mM DTT, 1 mM effector.  The ribozyme and 
substrate strands were annealed (each aptazyme separately) at 90 °C for 2 min, then 
cooled to room temperature over 5 min.  The reaction took place at room temperature 
for 2 h.  ATP aptazyme and glmS ribozyme cleavage reactions were performed under 
the following conditions unless otherwise noted: 150 nM aptazyme; 75 nM substrate; 50 
mM HEPES-KOH, pH 7.5; 200 mM KCl; 50 mM MgCl2; 25 mM DTT; 100 M ATP; 
and 10 M GlcN6P.  The ribozyme and substrate strands were annealed (each aptazyme 
separately), ATP aptazyme at 90 °C and glmS ribozyme at 70 °C for 2 min, then cooled 
to room temperature over 5 min.  The reaction took place at room temperature for 20 
min.  Reactions were separated by 20 % PAGE at 20 W for 2 hr and analyzed on a 
Typhoon Trio (GE Healthcare, Piscataway, NJ) using fluorescence detection with 
excitation at 488 nm and detection at 530 nm and the platen focal depth setting, with the 
gel placed directly on the glass platen.  Gel scans were analyzed with ImageQuant, 
dividing the intensity of the product band by the sum of the intensities of the product and 
substrate bands. 
 
Results and Discussion 
Design of trans-cleaving aptazymes.  Based on cis-cleaving constructs of 
aptazymes for cAMP and ATP, we designed trans-cleaving aptazymes by eliminating the 
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loop of stem III (Chapter 3, Figure 3-1).  We designed three substrates for these 
aptazymes, with different 3‟ ends in order to multiplex our assay, so that the ability to 
separate 3‟ cleavage products would be necessary.  All substrates were labeled with 
fluorescein on the 3‟ end (Chapter 3, Figure 3-1B-D). 
Multiplex of cAMP and ATP aptazymes.  We have previously demonstrated 
that the ATP and cAMP aptazymes have some experimental incompatibility for a 
multiplexed assay.  Namely, the ATP aptazyme cleaves faster than the cAMP aptazyme 
and at a lower MgCl2 concentration.  Furthermore, though the cAMP aptazyme is not 
activated by ATP, the ATP aptazyme is activated by cAMP.  One further complication 
is rooted in their design.  Because they were both designed with the hammerhead 
ribozyme as the catalytic portion of the molecule, their substrate is interchangeable.  
Nevertheless, we tested whether they could serve in a qualitative assay for simultaneous 
detection of cAMP and ATP.  We annealed them separately before mixing them and 
adding effector in an effort to reduce substrate exchange.  After reacting for 2 h, they 
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Figure 4-1. Multiplexed detection of ATP and cAMP.  A. PAGE of multiplex assay.  B. Bar graph 
representing increase in cAMP aptazyme product band upon effector mediated cleavage.  C. Bar graph 
representing decrease in ATP aptazyme substrate band upon effector mediated cleavage.  Effector is listed 
above bars.         
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In response to cAMP, the cAMP aptazyme is activated, whereas the ATP 
aptazyme is not.  This can be seen in Figure 4-1B, in which the cAMP aptazyme is 
represented in shades of red, and the ATP aptazyme in shades of green.  The cAMP 
aptazyme is not activated in response to ATP, as represented by the red bars.  When the 
two aptazymes were mixed for multiplexed detection, addition of cAMP resulted in a 
product band that was less intense than with cAMP aptazyme alone (Figure 4-1B, blue 
bars).  ATP also results in a cleavage product resulting from cleavage of the cAMP 
substrate.  As the cAMP aptazyme is not activated by ATP, these results suggest that 
substrate exchange occurs between the aptazymes at room temperature. 
Thus, we have developed a multiplexed experiment to qualitatively detect ATP 
and cAMP with their aptazymes.  Due primarily to cross-reactivity and substrate 
exchange, this assay is not quantitative.  These inherent challenges to detection could be 
addressed at the onset of an aptazyme design experiment by applying appropriate 
selection conditions for the desired outcome.  These preliminary experiments for 
multiplexing these aptazymes by gel electrophoresis show promise for future assays. 
Thus, we have developed a multiplexed experiment to qualitatively detect ATP 
and cAMP with their aptazymes.  Due primarily to cross reactivity and substrate 
exchange, this assay is not qualitative.  These inherent challenges to detection could be 
addressed at the onset of an aptazyme design experiment by applying appropriate 
selection conditions for the desired multiplex outcome.  Our current preliminary results 
for multiplexing these aptazymes coupled with analysis by gel electrophoresis show 
promise for future assays. 
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Multiplex of ATP and glmS aptazymes.  We decided to investigate a second 
pair of aptazymes for multiplex potential, which are not expected to suffer from cross 
reactivity and that cleave under similar reaction conditions.  They do not have similar 
substrate binding regions, therefore, substrate exchange is not expected to be a problem.  
These aptazymes were annealed separately and mixed before adding effectors and 
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Figure 4-2. Multiplexed detection of ATP and GlcN6P.  A. PAGE of multiplex assay.  B. Bar graph 
representing increase in ATP aptazyme product band upon effector mediated cleavage.  C. Bar graph 
representing increase in glmS ribozyme product band upon effector mediated cleavage.  Effector is listed above 
bars.  
 69 
As illustrated in Figure 4-2, the ATP aptazyme is not activated by GlcN6P (Figure 
4-2B, red bars), nor is the glmS ribozyme activated by ATP (Figure 4-2C, green bars).  
There is no evidence for substrate exchange.  When the aptazymes are mixed for 
multiplexed detection (blue bars), both analytes are detected, though the total fraction of 
aptazyme cleaved is lower than in the single aptazyme experiments.  Furthermore, the 
fraction cleaved is even lower when both analytes are present.  Nonetheless, we tried an 
assay for ATP and GlcN6P (Figure 4-3), in which both analytes were detected 
simultaneously by both aptazymes.  The calibration curves for both analytes are linear at 
low M concentrations of analyte, 0 M to 10 M for ATP and 0 M to 1 M for 











Figure 4-3. Calibration curve for multiplexed assay of ATP (●) and GlcN6P (■).   
        
 
Conclusions 
We have demonstrated potential for multiplexing aptazymes with PAGE detection.  
ATP and cAMP can be qualitatively detected using the ATP and cAMP aptazymes.  The 
glmS ribozyme and ATP aptazyme are more compatible for a multiplexed format, and 
can be detected at low M concentrations in a multiplexed assay.  Design of aptazyme 
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selection conditions could be changed to design aptazymes that address the potential 
problems of cross-reactivity and differential reaction conditions and times.  The analysis 
time could be improved by moving to a CGE system, which would also reduce 
preparation time, buffer and sample consumption, as well as improve peak quantitation 









SUMMARY AND FUTURE DIRECTIONS 
Summary 
This thesis has aimed to consider the role of nucleic acids for use in analytical 
assays.  In particular, we have focused on aptazymes for effector detection.  We have 
used three different aptazymes, glmS; cAMP; and ATP, and three different methods of 
detection, FRET; CE; and PAGE.  Aptazymes are appealing candidates for analytical 
assays because they can perform both analyte recognition as well as transduction of 
analyte binding to a detectable signal.  Furthermore, their often modular nature allows 
for design and selection of aptazymes to a multiplicity of targets, opening their potential 
to a broad range of molecules.  The application of aptazymes in analyte detection is a 
relatively open field, with much territory available for exploration.   
Assays for GlcN6P using the glmS ribozyme.  The glmS ribozyme is a natural 
aptazyme that cleaves in response to the effector molecule GlcN6P, resulting in the 
degradation of the ensuing mRNA.  This aptazyme is unique in its role as a metabolite 
sensitive genetic regulator, as the only one found in nature to date.  In bacteria, GlcN6P 
is used as a precursor to cell wall biosynthesis; preventing its synthesis could lead to cell 
death.  Thus, the glmS ribozyme is a potential target for antibiotic activity, and could be 
used for high-throughput screening in pharmaceutical development.  GlcN6P is also 




Increased flux of GlcN6P into this pathway has been shown to result in impaired ability 
of insulin to stimulate glucose uptake.
56
  Detailed characterization of this pathway could 
lead to insight into a mechanism of development of insulin resistance in cells.  Several 
methods have been developed for monitoring GlcN6P formation in this pathway, and 
though some are sensitive to pmol concentrations of GlcN6P,
57
 they all require multiple 
derivatization steps and/or radioactivity.  Ideally a detection method uses a minimal 
amount of sample, is fast, can be run in parallel or in array formats, and does not require 
elaborate design of the reagents.   
In this work, we developed several glmS ribozyme-based FRET and CE assays for 
the detection of GlcN6P.  In the trans-cleaving model, an external substrate is added to 
the glmS ribozyme and GlcN6P activated cleavage results in three RNA molecules: the 
cleavage product, a three nucleotide molecule; the cleaved substrate at eight nucleotides; 
and the unchanged ribozyme molecule, which is twenty three nucleotides in length.
51
  
We first monitored the kinetics of this single-turnover cleavage reaction by FRET to 
obtain an assay for GlcN6P based on the rate of the cleavage reaction.  As 3‟ cleavage 
product (fluorescein labeled) was produced and moved away from the 5‟ product 
(tetramethylrhodamine labeled), donor fluorescence increased until the reaction slowed, 
resulting in a plateau in fluorescence intensity.  The rate of the cleavage reaction, kobs, 
can be obtained by fitting the increase with a one-component exponential association 
function.  A linear regression of reaction rates versus concentration of GlcN6P results in 
an LDR of 0.5 M to 500 M and an R
2
 of 0.999.  The LOD is 800 nM.     
We wanted to add a separation step to the glmS ribozyme cleavage assay to create 
an assay for GlcN6P present based on the amount of cleavage product formed.  First, we 
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monitored the ribozyme kinetics by injecting samples every 12.5 s into a high-speed CE-
LIF instrument, separating substrate from product in less than 10 s.  The product peak 
heights were normalized and fit with a one-component exponential association function, 
reporting reaction rates that were comparable to those obtained by FRET.  In our free-
solution CE assay, we have an LDR of 0.5 M to 100 M (R
2
 is 0.998), as the calibration 
curve plateaus at lower concentrations than the rate-based FRET curve.  At higher 
concentrations of GlcN6P, the reaction has reached completion, thus different 
concentrations are indistinguishable.  This assay has a lower LOD (500 nM) than the 
FRET assay. 
We hoped to further improve the assay by using multiple-turnover kinetics for the 
aptazyme reaction.  In principle, this approach would lead to more signal for each 
effector molecule as the ribozyme cleaved multiple substrates.  In practice, the 5‟ 
product is complementary to the ribozyme with as many nucleotide pairs as the 
uncleaved substrate (19).  The data suggest that at temperatures below 50 °C, the 5‟ 
product does not dissociate from the ribozyme efficiently but that at 50 °C, the ribozyme-
substrate binding reaction reaches equilibrium.  At this temperature, the donor 
fluorescence signal is 2-fold greater after 40 min than the same reaction at 42 °C.  The 
LDR for the multiple-turnover CE assay (at 50 °C) is the same as the single-turnover CE 
assay (0.5 M to 100 M, R
2
 is 0.995), but the LOD is improved to 100 nM. 
The above results suggested that a two temperature cycle designed with one 
temperature (42 °C) to allow catalyzation of the cleavage reaction followed by a second 
temperature for substrate dissociation (60 °C) may further enhance signal amplification.  
Indeed, this is what we observed.  After 40 m, the signal is 4-fold greater than the same 
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reaction at 42 °C and 2-fold greater than at 50 °C.  The temperature-cycled, multiple-
turnover CE assay has the same LDR as the other CE assays (0.5 M to 100 M, R
2
 is 
0.999), with further improvement in LOD, to 50 nM. 
Both the FRET and CE methods appear to be useful for monitoring the glmS 
ribozyme cleavage reaction.  For kinetic measurements, the FRET reaction achieves a 1 
s temporal resolution compared to the 12.5 s possible by the CE-LIF method, which was 
crucial for gaining an understanding of the multiple-turnover cleavage reaction.  As an 
assay, the FRET method has a wider dynamic range; primarily because it was based on 
kinetic data rather than a fixed time point like the CE-LIF method.  For the same reason, 
the CE method was much faster, with each sample taking only seconds to analyze after 
completion of the cleavage reaction, rather than minutes or hours.  The CE method uses 
less analyte with sample volumes as low as 10 µL compared to 150 µL FRET samples.  
The LOD was improve from 800 nM for single-turnover FRET to 500 nM for single-
turnover CE, and improved further by multiple-turnover conditions at 50 °C, 100 nM, 
and cycled between 42 °C and 60 °C, 50 nM. 
Characterization of the ATP and cAMP aptazymes.  As the glmS ribozyme, a 
natural aptazyme, was effective in assays for GlcN6P, we wanted to investigate the 
potential of non-natural aptazymes.  These are especially appealing because they often 
have a modular nature, which allows for domain swapping.  That is, aptazymes have 
been broken into three domains, which are binding; communication; and catalytic 
domains, and they have be separated, swapped, and reassembled into new aptazymes.  
Aptamers have been used as the binding domains in some cases.  Thus, there already is 
a resource of known potential binding domains that could be tested with known 
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communication and catalytic domains for aptazyme function, as well as potential for 
evolving novel domains.  Adding a selection step after assembly (or to a random 
sequence) can lead to aptazymes that possess user-defined characteristics.  This research 
demonstrates the utility of such selection by comparing two aptazymes that were 
designed differently.  
The Breaker group used rational design to design an aptamer for ATP by coupling 
an RNA aptamer to the hammerhead ribozyme via a variable communication domain.
32
  
The ATP aptamer has a Kd of 0.7 M, and binds to adenosine and AMP with similar 
affinities.
61
  The same group developed an aptazyme that responds to cAMP by applying 
an allosteric selection scheme to a hammerhead ribozyme that was coupled to a 25 
nucleotide random sequence domain via a previously characterized communication 
domain.
37
  The selection involved both positive and negative selection steps, selecting 
for aptazymes that were specifically activated by cAMP and not other cNMP‟s and that 
had low background cleavage.  The apparent dissociation constant for this aptazyme 
was determined to be 500 M by measuring the half maximal cleavage activity.
38
   
We began by designing trans-cleaving aptazymes from the cis-cleaving molecules 
developed by the Breaker group.  We used PAGE with fluorescence detection to 
characterize the trans-cleaving ATP and cAMP aptazymes.  Both aptazymes were 
developed using the hammerhead ribozyme for the catalytic domain, so the binding 
regions of the substrate molecules were all identical and, thus, interchangeable.  We 
designed the substrates for these aptazymes with different 3‟ ends so that they could be 
separated in multiplexed experiments.  All substrates were labeled with fluorescein on 
the 3‟ end.  Characterizing the cleavage reactions of the aptazymes revealed some 
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incompatibilities for a multiplexed reaction.  They gave the best response to effector at 
different reaction conditions, and the ATP aptazyme cleaved much faster than the cAMP 
aptazyme.  Furthermore, though the cAMP aptazyme was not activated by ATP, ADP, 
AMP, or cGMP, the ATP aptazyme was activated by ADP, AMP, and cAMP.  During 
selection, the cAMP aptazyme was put through several negative selection steps, including 
some to reduce cross-reactivity.  These results suggest that development of aptazymes 
for multiplexed assays could be tailored to meet the specific needs of an assay, like the 
multiplexed assay that we investigated, by selecting molecules that cleave under the same 
reaction conditions, reducing cross-reactivity with negative selection steps, and selecting 
aptazymes that cleave at the same rate.   
The ability to simultaneously detect analytes in one assay holds great potential for 
rapid analysis necessary for detection and characterization of disease states, enzyme 
function and various high-throughput screening assays.  There is potential for use of 
multiplexed assays in metabolomics and as a clinical panel.  Despite the above 
incompatibilities, we were interested in trying to multiplex the ATP and cAMP 
aptazymes in a proof-of-principle asssay to help inform future aptazyme design for 
multiplexed assays.  With separation by PAGE and fluorescence detection, a qualitative 
measure of the presence of cAMP and ATP was achieved.  Both cross-reactivity and 
substrate exchange hindered the development of a quantitative assay, but these results 
encouraged us to try another system. 
The glmS ribozyme and ATP aptazyme do not have exchangeable substrates and 
do not show any cross-reactivity.  Their optimal reaction conditions are compatible, 
though the glmS ribozyme cleaves somewhat faster than the ATP aptazyme.  In the 
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multiplexed assay, the linear region was from 0 M to 10 M for ATP and 0 M to 1 M 
for GlcN6P.  The LOD‟s were 1 M and 40 nM for ATP and GlcN6P, respectively.  
These data demonstrate the feasibility of a at least somewhat quantitative multiplexed 
assay using aptazymes as recognition and transduction elements. 
Overall, this thesis demonstrates the utility of aptazymes in a variety of assays for 
the detection of three small molecules: GlcN6P, ATP, and cAMP.  FRET-based 
detection offered the advantage of 1 s temporal resolution for observing the glmS 
ribozyme cleavage reaction.  CE has the advantages of fast separations, low sample and 
reagent consumption, and good quantitation.  Multiple-turnover kinetics resulted in 
signal amplification and lowered the LOD of the assay.  Multiplexed assays 
demonstrated the potential for simultaneous, multi-analyte detection. 
 
Future Directions 
We have demonstrated the potential of aptazymes to serve as recognition and 
transduction elements in analytical assays.  Based on our current results, it seems 
promising that aptazyme-based assays could be improved and applied to a broad range of 
molecules.   
Multiple-turnover cleavage reactions of the glmS ribozyme.  In our multiple-
turnover reactions with the glmS ribozyme, we observed that it was necessary to elevate 
the reaction temperature to achieve multiple substrate turnovers.  The results of a 
temperature titration suggested that the 5‟ product was not efficiently dissociating from 
the ribozyme at the reaction temperature.  Further evidence came from temperature 
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cycled experiments, in which the ribozyme was alternately incubated at reaction and 
dissociation temperatures resulting in substrate turnover and signal amplification.   
Another potential method for achieving multiple turnovers with the glmS 
ribozyme could involve redesign of the substrate to reduce the base pairing between 
substrate and ribozyme.  This would reduce the binding interaction between those 
molecules and lower the temperature at which equilibrium would be expected.  As we 
saw with our cGMP aptazyme, changes in aptazyme structure may interfere with the 
cleavage reaction, so many glmS ribozyme variants may need to be designed in order to 
achieve reduced binding while retaining catalytic functionality.  A successful design 
could eliminate the need for an elaborate system of temperature cycling in the assay. 
Structure-function relationship of the cAMP and ATP aptazymes: trans 
versus cis.    In comparison to its cis-cleaving predecessors, the trans-cleaving cAMP 
aptazyme described in Chapters 3 and 4 requires a higher MgCl2 concentration and 
longer incubation times and still does not catalyze effector mediated cleavage reactions as 
well.  Upon activation by 500 M cAMP, the cis-cleaving aptazyme cleaves to greater 
than 35% completion after 40 min in buffer containing 20 mM MgCl2,
37
 whereas our 
trans-construct cleaves to less than 30% completion upon activation by 1 mM cAMP 
after 2 h in buffer containing 100 mM MgCl2.  These results suggest that the change in 
structure of the aptazyme led to reduced catalytic ability.  Perhaps the transition from an 
intramolecular reaction to an intermolecular reaction leads to reduced catalytic efficiency.  
The cGMP aptazyme, which we find does not cleave in trans under any conditions that 
we have tested though its cis-cleaving counterpart cleaves effectively, seems to 
corroborate this hypothesis 
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Our trans-cleaving ATP aptazyme, on the other hand, may cleave more rapidly 
than the cis-cleaving version, though more investigation into this is necessary, as we have 
not tested comparable cleavage conditions to the original paper.  They see a 40-fold 
activation of the aptazyme by ATP in 20 mM MgCl2 with 1 mM ATP, from a cleavage 
rate in the absence of effector of 0.000042 s
-1
 to 0.0017 s
-1
 when ATP is added.  We see 
a 4-fold activation with 1 mM ATP and 50 mM MgCl2, with an increase in rate of 
cleavage from 0.21 s
-1
 to 0.92 s
-1
.  Background cleavage of the trans-cleaving construct 
is higher than the cis-cleaving, and effector activation results in a smaller enhancement in 
the rate of cleavage.  Further study of this aptazyme may reveal that the high 
background is due to the higher concentration of MgCl2, which is known to cause RNA 
degradation. 
Testing several different trans-cleaving versions of the same aptazyme could help 
elucidate whether the cause of the change in cleavage efficiency can be explained by the 
separation of the aptazyme into two molecules.  Additionally, it may demonstrate what 
role, if any, the nucleotides removed play in modulating activity in the ATP, cAMP, and 
cGMP aptazymes.  Further investigation into this interesting area may also more 
generally inform trans-cleaving aptazyme design.   
CGE multiplex assays.  The multiplex assays in Chapter 4 were analyzed by 
PAGE with fluorescence detection, which was useful for analyzing a large number of 
samples in parallel.  The use of fluorescent labeling was an improvement over 
radiochemical detection by eliminating the need for radiochemicals, thereby increasing 
the lifetime of the samples, and simplifying sample handling.  Nevertheless, PAGE is a 
laborious process that consumes a lot of reagents and has relatively poor quantitation. 
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CGE is widely used for the separation of nucleic acid molecules and has been 
used to observe ribozyme cleavage.
66
  CGE has many advantages over PAGE including 
higher resolution, higher sensitivity, shorter analysis time, better quantification, less 
reagent consumption, and ease of automation.  Thus, these assays could be simplified by 
moving to a CGE format for separation and detection.   
To maintain (and increase) the parallel nature of the PAGE analysis, the assay 




 which are commercially available.  To 
miniaturize the instrument and further reduce sample and buffer consumption, 
microfluidic devices which are capable of parallel separations could be adapted to the 
assay.  Ribozyme cleavage reactions have previously been monitored on a microchip 
with overlapping, automated capillary injections.
67
   
Application of assays to real samples.  As an analyte, GlcN6P is potentially 
interesting in at least two different systems.  In bacteria, GlcN6P is a precursor in cell 
wall biosynthesis.  Therefore, identification of compounds that could activate glmS 
ribozyme cleavage and potentially inhibit cell wall biosynthesis could be advantageous in 
drug discovery.  The glmS ribozyme is highly conserved in genomes of some bacterial 
pathogens, like Bacillus anthracis and Staphylococcus aureus, making it a relevant 
detection target.
54
  GlcN6P is involved in the hexosamine biosynthetic pathway and 
increased flux into this pathway has been shown to result in impaired ability of insulin to 
stimulate glucose uptake.
56
  Detailed characterization of this pathway could lead to 
insight into a mechanism of development of insulin resistance in cells.  Thus, the 
application of the GlcN6P assays to real samples could be relevant for drug discovery or 
insulin resistance in cells.   
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Application of this assay to biological samples may require the use of non-natural 
bases.  RNA can be degraded in nature, so in some cases, non-natural bases have been 
used to alleviate this problem.
1
 
Design/select new aptazymes for interesting molecules.  After addressing 
some of the remaining questions surrounding the aptazyme assays we have developed, 
novel aptazymes could be selected for use in other assays.  The power of aptazymes as 
analytical tools lies in their versatility.  In principle, the ability to couple (or evolve) 
binding to catalyzing function allows the targeting of any molecule.  Given the results of 
Chapters 3 and 4, aptazymes could be designed with a random regions connected to 
ribozyme domains and put through a series of negative and positive selection steps.  In 
this selection scheme, buffer conditions and time allowed for selection could be chosen to 
reflect assay conditions.  Negative selection steps could be aimed at both reducing 
background cleavage as well as reducing cross-reactivity with molecules that are 
structurally similar to the target molecule.  It would be interesting to learn whether 
parallel aptazyme selection aimed at developing aptazymes for multiplex assays would be 
successful in producing compatible aptazymes. 
Further, incorporation of a different ribozyme module in the rational design of 
new aptazymes may result in faster cleavage, as has recently been demonstrated with a 
full-length hammerhead ribozyme in an aptazyme for theophylline.
96
  One of the 
selected aptazymes cleaves at a rate of 8 min
-1
.  In an assay, this increase in rate of 
cleavage could lower the LOD and increase the sensitivity. 
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The assays developed in this thesis demonstrate the potential of aptazymes in 
analytical assays.  Further development is necessary to increase specificity and 
sensitivity.  Additionally, the development of novel aptazymes will enhance their 
applicability in detecting biologically interesting compounds.  
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APPENDIX A 




Advances in understanding the complexity of cellular mechanisms depend upon 
methods that can quantify affinity interactions between biological molecules.  
Additionally, fields such as chemical biology and drug discovery require methods for 
identifying molecules that can probe these affinity interactions.  Aptamers or nucleic 
acids molecules that have been evolved to have non-natural binding interactions with 
targets of interest can be involved in methods for quantifying affinity interactions and 
screening for bioactive molecules. 
Aptamers are artificial, specific oligonucleotides that bind target molecules. Their 
sensitive and specific binding characteristics make them useful candidates for diagnostic, 
therapeutic, and analytical applications.  Aptamers are obtained through selective 
evolution of ligands by expontential enrichment (SELEX), a combinatorial ligand 
discovery process that evolves large, synthetic libraries of random sequence nucleic acid 
molecules in order to isolate ligands with high affinity and specificity to molecular 
targets.
2
  An oligonucleotide library is exposed to the target of interest, and subsets of 
sequences that have affinity are partitioned from those sequences with little or no affinity.  
The process is iterative, typically involving ten to fifteen rounds of selection with 
increasing stringency and ending when a set of ligands with the desired binding 
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characteristics is obtained. This set of ligands is cloned into bacterial plasmids and 
individual sequences determined by sequencing.  The isolated ligands are termed 
aptamers.   SELEX has been used to isolate molecules to a broad range of targets, from 
small molecules to large proteins.  
 
 
Figure A-1. SELEX. 




 different nucleic acid sequences.  
Each molecule consists of a segment of random sequence flanked by primer binding sites 
at each end for enzymatic amplification.  Theoretical library size can be determined by 
4
n
 where n is the number of randomized positions in the molecules.  Actual library size 




 molecules in a single reaction.  Base pairing and other sequence 
dependent intramolecular interactions vary among the molecules, providing a large 
number of different tertiary structures in the library population.  Among these are some 
commonly recognized motifs: hairpins, bulges within helices, pseudoknots, and G-
quartets, among others.  Biological function, including binding affinity, is determined 
by the shape and charge characteristics of each molecule. 
Affinities of aptamers for their target molecules can be quite high, with 
dissociation constants extending down into the picomolar range.
7, 8
  These affinities rival 
or exceed the capabilities of antibodies, making aptamers good candidates for analytical 
assays.  The evolution process enables control over kinetic and thermodynamic 
properties of the aptamer-target binding interaction. 
Aptamers have been demonstrated to be viable replacements for antibodies in 
many immunological experiments.  In fact, oligonucleotides provide significant 
advantages over antibodies in several regards.
9
  Many of these come from the evolution 
process, which allows the in vitro development of aptamers as opposed to the in vivo 
development of antibodies.  Beyond the advantage of avoiding the need for animals in 
development, the in vitro selection process confers the advantage of a wider range of 
target molecules by including those that would be toxic in vivo as well as those that 
would not induce an immune response.  Due to the reliability of chemical synthesis of 
aptamers after they have been sequenced, less batch-to-batch variation is expected than is 
expected for antibodies, which are always produced in vivo.  Aptamers are more stable 
for long-term storage than antibodies, and can be restored even after denaturation.  
Aptamers can be modified after selection to further optimize binding affinities or to add 
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modified bases to prevent degradation if they will be introduced to biological sample.  
Further, no immunogenicity is expected from aptamers if they are introduced to the body.  
Finally, reporter molecules such as fluorescein and linkers such as biotin can often be 
easily attached to aptamers at precise locations without disrupting their activities. 
Thus, aptamers can be used in both diagnostic and therapeutic applications that 
are based on molecular recognition.  Possible uses include affinity purification of 
proteins, in vitro and in vivo diagnostic work, imaging, drugs, and specific detection and 
precise quantification of molecules.  They have been used in analytical applications 
including flow cytometry, biosensors, affinity probe capillary electrophoresis, capillary 
electrochromatography, and affinity chromatography.    
Part of this thesis (unsuccessfully) aimed to develop an aptamer for insulin that 
would be employed in two novel approaches to the direct detection of insulin with a 
spatially and temporally resolved measurement of secretion by single cells.  Diabetes is 
estimated to affect 6.2% of the population of the United States, or 17 million people.  
About one third of these cases have not yet been diagnosed.  Diabetes carries an 
increases risk for a wide range of disorders including heart attack, stroke, blindness, 
damaged kidneys and kidney failure, nerve damage, skin disorders, and gum disease.  
Ninety to ninety-five percent of diabetics have type II diabetes, which is caused by 
defective insulin secretion by pancreatic β-cells.  High resolution monitoring of insulin 






Chemicals.  DNA library was purchased from Integrated DNA Technologies 
(Coralville, IA).  All solutions were prepared with deionized water from an E-Pure 
water purification system (Barnstead International Co., Dubuque, IA).  Taq DNA 
polymerase was purchased from Invitrogen (Carlsbad, CA).  T7 RNA polymerase was 
expressed and purified according to the protocol in Appendix B.  Bovine insulin and 
bovine insulin immobilized on 4 % beaded agarose were purchased from Sigma 
Chemical Company (St. Louis, MO). 
Preparation of RNA library.  DNA was designed with two primer binding 
regions on either end, flanking a 40 nucleotide region of random sequence.  The 
sequence was as follows: 5‟GGG AGT CGA CCG ACC AGA A (N40) T ATG TGC 
GTC TAC ATC TAG ACT CAT 3‟.  A T7 promoter sequence was added by 
polymerase chain reaction (PCR) using 1 µM each primer, 5‟ CAG TAA TAC GAC 
TCA CTA TAG GAT GAG TCT AGA TGT AGA CGC ACA TA 3‟ and 5‟ GGG AGT 
CGA CCG ACC AGA A 3‟, 500 nM library, 1 X PCR buffer, 3.0 mM MgCl2, 200 µM 
dNTPs, and 0.073 U/µL.  The DNA was concentrated with 2-butanol, extracted with 
phenol/chloroform/isoamyl alcohol followed by chloroform/isoamyl alcohol, and ethanol 
precipitated. The RNA was transcribed from this DNA template at 37 °C in an overnight 
reaction using the following optimized reagent concentrations: 2000 nM DNA library; 4 
mM NTP mixture; 120 mM HEPES-KOH, pH 7.5; 30 mM MgCl2; 2 mM spermidine; 40 
mM DTT; 0.04% triton X-100; 0.005 U/µL; 0.1 mg/mL T7 RNA polymerase; and 8% 
polyethylene glycol.  The reaction was quenched with 60 mM EDTA, pH 8.0, and the 
RNA was extracted with phenol/chloroform/isoamyl alcohol followed by 
 89 
chloroform/isoamyl alcohol, concentrated with a 3000 kD centricon filter.  The RNA 
was then purified on a 15 % polyacrylamide gel, the band was cut out, crushed and 
tumbled overnight in crush „n‟ soak buffer, chloroform extracted, and concentrated with a 
3000 kD centricon filter.  The concentrations of all nucleic acid samples were 
determined using their absorbance at 260 nm. 
Insulin filter binding for selection.  Insulin binding to various membranes was 
determined by flowing FITC-insulin in binding buffer (118 mM NaCl, 5.4 mM KCl, 1.2 
mM MgSO4, 1.2 mM KH2PO4, 20 mM HEPES, pH 7.5) through the membrane with a 
syringe pump at about 20 L/min.  The insulin was eluted from the filter by flowing 60 
% acetonitrile in water through the filter. The fluorescence intensities of the original 
sample, flow through, and eluant were measured on a Perkin Elmer Fusion Universal 
Microplate Analyzer (Packard Instrument Company, Meriden, CT).  Fluorescence was 
excited at 485 ± 10 nm and emission collected with a 535 ± 12 nm bandpass filter.  
Insulin filter binding was tried on the following filters: 0.1 M and 0.22 M mixed 
cellulose esters (Millipore, Billerica, MA), 0.45 M nylon (Fisher Scientific, Waltham, 
MA), Immobilon-P (0.45 M polyvinylidene fluoride) (Millipore, Billerica, MA), and 
Immobilon-PSQ (0.2 M polyvinylidene fluoride).   
SELEX experiments.  All SELEX experiments were conducted in binding 
buffer.  Negative selection was performed on 4 % agarose beads (300 m).  The beads 
were washed with binding buffer in a mini column (Pierce, Milwaukee, WI), centrifuging 
for 30 s at 8,000 x g between washes. The RNA library was annealed by heating to 70 °C 
for 5 m and cooled to room temperature on the benchtop.  The RNA library was then 
incubated with the beads for 25 m at room temperature with tumbling.  The sample was 
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centrifuged and washed twice with binding buffer.  The eluant and washes were 
collected and concentrated and the RNA was put through rounds of positive selection.   
Two types of positive selection were carried out in parallel.  In both types, insulin 
immobilized on 4 % beaded agarose was washed 10 times with binding buffer.  
Annealed RNA was added to the column and incubated at room temperature for 30 m 
with tumbling.  The column was washed 10 times and the RNA was eluted by adding 
8.0 mM insulin and incubating at room temperature for either 5 minutes or overnight.  
The insulin-bound RNA was then eluted from the column, phenol/chloroform extracted, 
ethanol precipitated, and reverse transcribed.  The cDNA was double stranded, 
extracted, precipitated, and transcribed.  The resulting RNA was gel purified and 
selected in another round of SELEX.  Ten total rounds were performed, with a negative 
selection step before round one. 
Measuring SELEX progress.  The RNA winners from rounds five and ten were 
radioactively labeled.  After annealing, the labeled RNA was incubated with 
immobilized insulin for 30 m with tumbling.  RNA aliquots from various stages of the 
preparation was transferred onto a nitrocellulose filter and dried.  These aliquots 
included RNA before insulin binding, RNA in flow through, RNA in eluted in wash 
steps, RNA eluted with 8.0 mM insulin, and RNA eluted with binding buffer at 95 °C.  
the gel was exposed overnight and quantified using a PhosphorImager Storm 840 with 





Results and Discussion 
Library design.  A single stranded DNA library was chemically synthesized 
(Integrated DNA Technologies, Coralville, IA).  Each member of the library had a 19 
base amplification region on the 5‟ end and a 24 base amplification region on the 3‟ end, 
as previously described.
97
  There was a 40 base variable region of random sequence 










are expected.  From this template, an RNA library was transcribed and subsequently 
evolved by SELEX to bind to insulin. 
SELEX.  Insulin is a 6 kD protein, which is relatively small compared to the 26 
kD nucleic acids used in our SELEX experiments.  We were concerned that its 
relatively small size may necessitate the use of a free solution selection process so as to 
avoid having the molecules tethered to a surface or bead.  In an effort to conduct the 
selection this way, we   Many ways of separating target-bound nucleic acids from 
unbound oligonucleotides have been employed, including filtration through nitrocellulose 
filters, chromatographic fractionation in which the target is immobilized on a solid 
support, gel electrophoretic and capillary electrophoretic partition in which the target-
bound oligonucleotides are physically separated from unbound oligonucleotides on the 
bases of their electrophoretic mobility.
98
  The most widely used partition method is 
nitrocellulose filtration, which has the benefits of simplicity and convenience as well as 
the ability to conduct the binding experiment in free solution.  We rationed that the free 
solution advantage would be particularly appealing for selection of an aptamer that is 
specific to insulin, because it is a very small protein at only 6 kD.   
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We first set out to determine the amount of insulin that would bind to various 
filters by pumping a solution of FITC labeled insulin dissolved in binding buffer through 
one or more filters with a syringe pump and measuring the relative fluorescence of the 
flow through.  Nitrocellulose is the most common filter material used for protein filter 
binding assays, but insulin did not bind well except when flowed through three filters.  
Nylon, Immobilon-P, and Immobilon-PSQ showed similar results.  Both of the 
Immobilon filters are made of polyvinylidene fluoride (Table 1).  The best binding was 
observed with Immobilon PSQ, but with only 70 % efficiency, we were concerned about 
the potential of losing 30 % of the tight binding nucleic acid molecules.  Instead, insulin 















Filter membrane Relative fluorescence in flow through (%)  
Nylon – 1 filter 
Nitrocellulose – 1 filter 
Nitrocellulose – 3 filters 
Immobilon P – 1 filter 
Immobilon P – 3 filters 
Immobilon PSQ – 1 filter 










Table A-1. Relative fluorescence detection of FITC-insulin in flow through filter.  
 
Ten rounds of SELEX experiments were conducted in an effort to obtain an 
aptamer for insulin.  Preceding these was a negative selection step, performed on 4 % 
agarose beads (300 m) to remove agarose binding nucleic acids from the selection pool.  
The positive selection steps involved incubation of RNA with immobilized insulin for a 
short (5 m) and long (12 h) incubation.  To add additional selection pressure, we 
collected winning RNA molecules via a competitive binding assay, where free insulin in 
binding buffer was added to the binding experiment after the wash steps.  Thus, only 
insulin binders would elute from the column, further reducing the number of non-specific 
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binders in the pool.  We reasoned that tight binders may also have slow off rates, thus 
we designed two sets of elution conditions.  In the first, the competitive binding was 
conducted for 5 m, whereas the other sample was incubated with free insulin for 12 h.  
We anticipated finding more binders in the long elution samples. 
  After five rounds of selection, the progress of the evolution was monitored by 
incubating radiolabeled RNA with immobilized insulin.  After the incubation, RNA was 
eluted in several steps and small aliquots were transfer to a membrane, which was 
analyzed for intensity of radioactivity (Figure 2A).  Comparing the total RNA bound to 
the immobilized insulin between the original library and the two evolved pools showed 
no significant difference in binding affinity.  Looking closer at the binding profile by 
comparing between the pools RNA that washed off with binding buffer, RNA that eluted 
off in a competition with insulin, and RNA that eluted off of the column with 95 °C 
binding buffer also showed no difference in affinities between the pools (Figure 2B).  
Based on these results, we concluded that there was no progress in the evolution up to 
round 5.  We therefore decided not to increase the stringency of the binding reaction, as 
is typically done in SELEX experiments in later rounds of selection when the pool‟s 
affinity for the target molecule is increasing.  Instead, the library was subjected to five 





Figure A-2.  Progress of SELEX after five rounds of selection. 
 After ten rounds of selection, the progress was monitored in the same way as after 
five rounds.  Similarly, no significant progress was observed in the evolution of the 
library (Figure 3).  In fact, the amount of RNA that eluted with insulin and 95 °C 






Figure  A-3.  Progress of SELEX after ten rounds of selection. 
 In SELEX, progress is usually observed before the tenth round of selection.  
Thus, we decided to end our pursuit of an aptamer for insulin.  We hypothesize our 
failure to select an aptamer could be due to the small size of insulin relative to the nucleic 
acid molecules as well as insulin‟s negative charge at the pH used for selection (7.5).  
Insulin has a pI of 5.5.  Given the negative nature of nucleic acids, binding to insulin 
may have been unfavorable.    
It is possible that alterations in the selection protocol may have led to the 
successful discovery of a high affinity aptamer.  For example, bias or hindrance 
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introduced by immobilization of insulin and poor kinetics of eluting very strong binders 
could have contributed to the lack of evolution in our experiments.  Two free solution 
selection methods that might effective are gel mobility shift and capillary electrophoresis.  
Finally, Larry Gold of SomaLogic, Inc., and one of the developers of the SELEX process 
has reported only a 60 % success rate in obtaining an aptamer with suitable binding 
characteristics in the first round of selection, suggesting our findings may not be unusual. 
 
Conclusions 
In this work, we investigated the potential of SELEX to obtain an RNA aptamer 
for insulin.  We were unsuccessful in evolving the original library to have increased 
affinity for insulin.  We hypothesize that this could be due to the small size of insulin 
relative to the aptamers or to insulin‟s negative charge at the pH used for selection.  It is 




T7 HIS TAGGED RNA POLYMERASE PREPARATION 
 
The pRC9 plasmid expresses a His-tagged T7 RNA Polymerase with a mutation 
that reduces 3’heterogeneity. Purification is BASED on the protocol from [He et 
al., Protein Expression and Purification 9: 142-151 (1997)]. 
 
Materials: 
A gravity flow through column with ~50ml volume 
25ml Chelating Fast Flow Sepharose beads (Amersham cat# 17-0575-01) 
Dialysis tubing ( the T7 Pol is ~100kDa or 100,000g/mol) 
 
Stock solutions (all except NaCl and LB should be sterile filtered): 
 
For the Transformation and Cell Culture (days 1, 2, & 3): 
2.5L LB broth (10 g trypton, 5 g yeast extract, 10 g NaCl, 1 L H2O, pH to 7.0 with 1M 
NaOH) – autoclave, add amp
100
 after cooled 
3mL SOC broth 
4 LB/Amp
100
 agar plates 
50mg/ml ampicillin frozen stock (add to LB right before use) 
 
For the IPTG Induction and Cell Wash (day 3): 
2mL of 0.4M IPTG either made right before use or from unused frozen stock 
100mL of 1M Tris pH 8.0 
10mL of 0.5M Na2EDTA pH~8.0 (to be used again in buffers for cell lysis/wash/elution) 
 
For Protein Collection and Column Preparation (day 4):  
4ml of 10mg/ml lysozyme either made fresh of from unused frozen stock 
1ml of 20mg/ml (0.115M) PMSF in isopropanol from frozen stock (careful it‟s toxic) 
10ml of 2M Tris base 
 
100ml of 1.5M Potassium Glutamate (not glutamic acid) 
100ml of 300mM HEPES 
100ml of 0.1% Tween-20 
100ml of 5M NaCl – autoclaved 
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100ml of 1M imidazole pH 7.5 
 
50ml of 1M Tris pH 7.2 
200ml of 1M KCl 
100mL 1M DTT 
2L glycerol 
 
50ml of 0.1M NiSO4 
 
150mL of 0.5M NaCl – autoclaved 
100mL of 1M NaOH 
 
Use the above in the preparation of the following: 
Lysis Buffer – 150mM K-Glu, 30mM HEPES, 0.05% Tween-20, 250mM NaCl, 5mM 
Imidazole 
Wash Buffer – Lysis Buffer, with 20mM Imidazole 
Elution Buffer – Lysis Buffer, with 100mM Imidazole 
Storage Buffer – 10mM Tris pH 7.2 (at 25C), 50mM KCl, 0.1mM EDTA, 1mM DTT, 
50% glycerol 
 
Induction of Protein Expression (from 2L LB) 
 
Day1: Transform BL21(DE3)pLysS cells (Promega) with pRC9 plasmid and plate on LB 
plates containing 100g/ml ampicillin overnight at 37C. 
 
Transformation Protocol: 
1. Thaw competent cells on ice. 
2. Pipet 65L cells into three microcentrifuge tubes, on ice 
3. Add 1-50ng DNA (but no more than 10L total volume added) per 10L cells.  
Flick  tube to mix.(ex: 3 x 65L aliquots to include T7 and controls, as follows: 
1.5L pRC9 (15ng/L) – T7 plasmid 
   2.5L pGEM3Z (0.1ng/L) – Promega, Amp
R
 = positive control 
   2.5L H2O – negative control) 
4. Incubate on ice for 15 minutes 
5. Heat shock for 45-50 seconds at 42C (no shaking) 
6. Incubate on ice for 2 minutes 
7. Add 900L cold SOC medium to each tube, incubate at 37C for 60 minutes 
(with shaking) 
8. Plate onto three LB/Amp100 (100g/mL ampicillin) plates 
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9. Incubate at 37C overnight 
    
Day2:  Check for healthy colonies on the T7 and positive control plates (and no growth 
on the negative control plate).  If the colonies look good, pick two fresh colonies 
from the T7 plate in the morning, and streak them out onto opposite sides of an 
LB/Amp
100
 agar plate.  Incubate at 37C.  By evening, healthy single colonies 
should be on both sides of the plate.  Choose one of these colonies to inoculate 
50ml LB/Amp
100
. This should be done late at night because it is preferable to use 
the cell culture when the OD600 is around 1, which takes roughly ~10-12 hours. 
 
Day3:  Induce T7 Production with IPTG 
 
Induction Protocol: 
1. Add 4 x 10mL of overnight cell culture to 4 x 500mL LB/Amp100 broth in 4 x 1L 
sterile erlenmeyers. 
2. Incubate at 37C and ~225rpm until OD600 is 0.4-0.7 (~ 4 hours).  
3. Remove and store 50L of culture to analyze with PAGE 
4. Add 4 x 500L of 0.4M IPTG to each flask (final conc = 0.4 mM IPTG) 
5. Incubate at 37C and ~225rpm for 4 hours 
6. After 4 hours, harvest cells by centrifugation for 15min, 5,000 x g, 4˚C 
(Fierke/Marsh lab centrifuge(s)).  
7. Resuspend the 2 pellets with 2 x 100mL cold 50mM Tris pH 8.0+5mM EDTA. 
8. Remove and store 50L of culture to analyze with PAGE 
9. Transfer to  4 x 50mL falcon tubes and centrifuge (Walter or Mapp lab) at 
9,000rpm, 15min, 4C and then store at –70C overnight.  
10. Run SDS-PAGE (use a pre-cast gel – Trycine from Invitrogen) on the two 50L 
fractions (Can be done on day 4): 
a. For each fraction: 10L cells + 10L dye, heat to 90C for 3 minutes, 
cool, load 10L total into each lane.  Run at 150V, until bromophenol 
blue line is near the bottom of the gel.  (dye = denaturing loading buffer 
(10 mL): 1mL glycerol, 2mL 1M DTT, 3mL 10% SDS, 1.25mL 1M Tris-
HCl, pH 6.8, 2.75mL 0.025 % bromophenol blue in H2O) 
b. Stain for 30 minutes (staining solution: 0.5g R250 Coomassie Blue, 
100mL methanol, 100mL H2O, stir until dye dissolves then stir in 20 mL 
acetic acid). 
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c. Destain until protein bands can be clearly seen, may take overnight, but 
results will be clear in about one hour (destaining solution: 450mL 
methanol, 475mL H2O, 75mL acetic acid). 
 




1. Resuspend each of the 4 pellets in 40mL Lysis buffer.  
2. Add 2M Tris base until pH >8 using pH paper.  
3. Pool all four pellets into a beaker, add 4mL of 10mg/ml lysozyme and 0.7mL 
0.115M (20mg/ml) PMSF, and incubate at room temperature for 15 minutes.  
4. Freeze at –70C (can be done overnight or until frozen), thaw at room 
temperature in water bath.  
5. Sonicate over ice at setting 8, 8 x 15 second pulses with 20 second breaks (Marsh 
lab, large tip).  
6. Spin down the 4 x 40mL at 10,000rpm, 1C, for 30 minutes.  Remove the 
supernatant and store at 4C (not overnight, if possible). 
Column Material Preparation: 
1. Centrifuge 10mL of Chelating Fast Flow Sepharose beads stored in 20% ethanol 
at 500 rpm, room temperature, for 3 to 5 minutes. 
2. Pour off supernatant, resuspend in  40mL of autoclaved ddH20, repeat 
centrifugation. 
3. Pour off supernatant, resuspend in 25mL of 50mM NiSO4, tumble at 4C for 30 
minutes.  Centrifuge as above. 
4. Pour off supernatant, resuspend in 40mL of autoclaved ddH20, centrifuge, pour 
off supernatant.  Repeat 2 times. 
Column Loading and Protein Collection: 
1. Resuspend beads in the ~160mL supernatant from the lysed cells into 4 x 50mL 
falcon tubes and gently tumble at 4C for 30 minutes. 
2. Pack the beads onto the column. Can use 10ml syringe stopper to increase flow 
rates. The column is run at room temperature 
3. Wash beads with wash buffer until OD280 <0.1 (around 100ml) using pure wash 
buffer as the blank.  
4. Gravity elute the polymerase with ~90mL elution buffer.  Collect 1st 10mL in 
falcon tube, then collect 1.5mL fractions in microcentrifuge tubes (~60) until the 
last of the 90ml reaches the top of the column material. As you collect fractions 
close the tubes and place them at 4C or on ice.  (Or use fraction collector and 
~4mL collection tubes – Fierke lab)   The elution can be monitored at OD280. 
Column Material Regeneration: 
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1. Strip the column of nickel by washing the beads with 10 column volumes of 
0.05M EDTA, 0.5M NaCl.   
2. Remove residual EDTA by washing with 2 to 3 column volumes of 0.5M NaCl.   
3. Remove precipitated proteins and hydrophobically bound proteins and sanitize the 
column material by soaking it in 100mL of 1M NaOH for 2 hours.  
4. Centrifuge the beads at 500 rpm for 5 min at room temperature.  
5. Pour off the supernatant, wash twice with autoclaved ddH2O. 
6. Resuspend in ~75mL of 20% ethanol for storage at 4C in a pyrex bottle. 
Protein Dialysis: 
1. Run pre-cast SDS-PAGE gels to look for the polymerase (every third fraction).  
(as on Day 3, step 10.) (or make your own, recipes follow.) 
2. Pool the polymerase-containing fractions in a dialysis bag pre-equilibrated in 2L 
of Storage Buffer at 4C. Dialyze overnight at 4C, with gentle stirring. After ~12 
hours change to a fresh 2L of Storage Buffer and dialyze again for ~12 hours at 
4C.  
3. Aliquot the diasylate into 1.5mL microcentrifuge tubes and store at –20C.   
4. Measure protein concentration using the dialysis buffer as a blank.  The 






, the path length 
of the cuvette is 1cm and the MW is 100 kDa. 
5. Run an analytical transcription of the material along with control reactions you 
know should work to validate functionality. 
 
To Prepare an SDS-PAGE gel: 
Make 2 SDS-Page gels (using 1.5 mm spacers)  
                  5 % stacking gel:   Volume 
40% polyacrilamide   3.75 mL 
1M Tris-HCl, pH 6.8   3.75  mL 
  ddH2O     20.4  mL 
  10% SDS    0.300 mL 
  10% APS    0.300 mL 
  TEMED    0.03 mL 
 
a. 10% running/resolving gel: 
40% polyacrilamide   25 mL 
1M Tris-HCl, pH 8.8   37.5 mL 
ddH2O     35.5 mL 
10% SDS    1 mL 
10% APS    1 mL 
TEMED    0.040 mL 
 
b. 4X Running buffer (1L): 
Tris base    12 g 
Glycine    57.6 g 
For 1X running buffer (2L) 
4X running buffer   500 mL 
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10% SDS    20 mL 
 
c. Denaturing loading buffer (10 mL): 
Glycerol    1mL 
1M DTT    2 mL 
10% SDS    3 mL 
1M Tris-HCl, pH 6.8   1.25 mL 
0.025 % bromophenol blue in H2O 2.75 mL 
 
1. After setting up plates, pour the resolving gel about 1-inch below where the comb 
bottom will be located.  Let the solution settle in the vertical position and using a 
Pasteur pipette, overlay the gel with about 0.5-inch of ddH2O.  Let gel set and tag 
the interface between water and gel. 
2. After the gel is set (20 minutes), pour off the water and add the stacking gel with the 
comb (10 lanes) . Allow this gel to set.  (Note: stacking gel polymerizes very 
quickly.). 
3. For fractions, remove 20L from every third fraction and combine with 20L 
denaturing loading buffer. In two tubes add 2l control T7 polymerase. 
4. Heat all samples to 90°C for 2 minutes and then ice for 2 minutes.  Load 30L into 
each well.  Run gel at 150V while bromophenol blue is in the stacking gel.  
Increase the voltage to 250 V when bromophenol blue is in the resolving gel.  Run at 
least, until the bromophenol blue is below the metal plate (about 2.5 hours). 
5. Stain gels for 15 minutes in staining solution and then de-stain the gels overnight (you 
can get a first impression of you results after the first hour).  
a. Staining solution (this solution should be reused): 
R250 Coomassie Blue    0.5 g 
Methanol      100 mL 
H2O       100 mL 
Stir until dye dissolves then stir in: 
20 mL acetic acid 
b. De-staining solution (Note: this solution can be reused): 
Methanol      450 mL 
H2O       475 mL 
Acetic acid      75 mL 
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